Document:

exv4w6

Exhibit 4.6

ACTION BY WRITTEN CONSENT

OF THE STOCKHOLDERS OF

FLUIDIGM CORPORATION

Effective as of August 25, 2008

     In accordance with Section 228 of the Delaware General Corporation Law and the Bylaws of
Fluidigm Corporation, a Delaware corporation (the “Company”), the undersigned, constituting
the holders of outstanding shares of stock of the Company having not less than the minimum number
of votes that would be necessary to authorize or take action at a meeting at which all shares of
the Company entitled to vote thereon were present and voted, hereby adopt the following resolutions
which shall be effective as of the date that the minimum number of votes necessary to effect the
following resolutions are received by the Company:

Consent to Automatic Conversion of Preferred Stock

WHEREAS: Section 4(b) of the Company’s Amended and Restated Certificate of
Incorporation (the “Current Certificate”) provides as follows:

“Automatic Conversion. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then
effective Conversion Rate for such share:

     (x) immediately prior to the closing of a firm commitment underwritten initial
public offering on Form S 1 (or successor form) filed under the Securities Act of
1933, as amended (the “Securities Act”), covering the offer and sale of the
Corporation’s Common Stock, provided that the offering price per share is not less
than $5.69 (as adjusted for subdivisions and combinations of the Common Stock and
changes in the Common Stock as set forth in Sections 4(e) and 4(g)) and the aggregate
gross proceeds to the Corporation are not less than $25,000,000, or

     (y) upon the receipt by the Corporation of a written consent or request for such
conversion from the holders of two-thirds of the shares of Preferred Stock then
outstanding, or, if later, the effective date for conversion specified in such
requests.

WHEREAS: The Company is currently in the process of completing an initial public
offering of its Common Stock, as described in the Company’s Registration Statement on Form
S-1 (Registration No. 333-150227) (the “Offering”).

WHEREAS: The undersigned holders collectively hold at least two-thirds of the shares
of Preferred Stock now outstanding.

 

 

WHEREAS: The undersigned holders of Preferred Stock of the Company believe it to be
in the best interests of the Company and its stockholders for all outstanding shares of
Preferred Stock to be converted to Common Stock at the then applicable Conversion Rate (as
defined in the Current Certificate) prior to the closing of the Offering, subject only to
the conditions set forth herein.

NOW, THEREFORE, BE IT RESOLVED: That, effective at 9:00 am Eastern on the third
business day prior to the closing of the first sale of Common Stock in the Offering, and
subject only to the approval of the price per share at which Common Stock is to be sold in
the Offering by at least 75% of the members of the Board of Directors of the Company, all
outstanding shares of Preferred Stock of the Company shall automatically and without further
action on the part of the holders of such Preferred Stock be converted into shares of Common
Stock of the Company in accordance with Section 4(b)(y) of the Current Certificate.

RESOLVED FURTHER: That any and all actions taken by the directors and officers of
the Company to carry out the purposes and intent of the foregoing resolutions prior to, on
or after their adoption are authorized, approved, ratified and confirmed.

* * * * *

 

 

     This action by written consent shall be effective as of the date the Company receives the
requisite consent of the Company’s stockholders. By executing this action by written consent, each
undersigned stockholder is giving written consent with respect to all shares of the Company’s
preferred stock held by such stockholder in favor of the above resolutions. This action by written
consent may be executed in any number of counterparts, each of which shall constitute an original
and all of which together shall constitute one action. Any copy, facsimile or other reliable
reproduction of this action by written consent may be substituted or used in lieu of the original
writing for any and all purposes for which the original writing could be used, provided that such
copy, facsimile or other reliable reproduction is a complete reproduction of the entire original
writing. This action by written consent shall be filed with the minutes of the proceedings of the
stockholders of the Company.

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	AllianceBernstein Venture Fund I, L.P.
	Date:	 	8/14/08
	 	By:	 	AllianceBernstein ESG Venture Management, L.P., its general
partner
	 	By:	 	AllianceBernstein Global Derivatives Corporation, its general
partner
	 	By:	 	/s/ Mona Bhalla
	 	Name:	 	Mona Bhalla
	 	Title:	 	Vice President

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Alloy
Ventures 2005, L.P.
	Date:	 	8/12/08
	 	By:	 	Alloy Ventures 2005, LLC
its General
Partner
	 	By:	 	/s/ Craig C. Taylor
	 	Name:	 	Craig C. Taylor
	 	Title:	 	Managing Member of Alloy
Ventures 2005 LLC
Managing Member of Alloy Ventures 2005, L.P.
	 	Alloy
Ventures 2002, L.P.
Alloy Partners 2002, L.P.
	Date:	 	8/12/08
	 	By:	 	Alloy Ventures 2002, LLC
its General
Partner
	 	By:	 	/s/ Craig C. Taylor
	 	Name:	 	Craig C. Taylor
	 	Title:	 	Managing Member of Alloy
Ventures 2002 LLC
Managing Member of Alloy Partners 2002, L.P. and
Alloy Ventures 2002, L.P.

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	Date:	 	8-14-08
	 	/s/ Bruce
Burrows
	 	Bruce Burrows

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	EuclidSR
Partners, L.P.
	Date:	 	August 12, 2008
	 	By:	 	EuclidSR Associates, L.P.
its General Partner
	 	By:	 	/s/ Elaine V. Jones
	 	Name:	 	Elaine V. Jones
	 	Title:	 	General Partner
	 	EuclidSR
Biotechnology Partners, L.P.
	Date:	 	August 12, 2008
	 	By:	 	EuclidSR Biotechnology Associates, L.P.
its General Partner
	 	By:	 	/s/ Elaine V. Jones
	 	Name:	 	Elaine V. Jones
	 	Title:	 	General Partner

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Fidelity
Contrafund:
Fidelity Advisor New Insights fund
	Date:	 	8/25/08
	 	By:	 	/s/ Paul M. Murphy
	 	Name:	 	Paul M. Murphy
	 	Title:	 	Assistant Treasurer
	 	Fidelity
Contrafund:
Fidelity Contrafund
	Date:	 	8/25/08
	 	By:	 	/s/ Paul M. Murphy
	 	Name:	 	Paul M. Murphy
	 	Title:	 	Assistant Treasurer
	 	Variable
Insurance Products Fund II:
Contrafund Portfolio
	Date:	 	8/25/08
	 	By:	 	/s/ Paul M. Murphy
	 	Name:	 	Paul M. Murphy
	 	Title:	 	Assistant Treasurer

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Interwest
Partners VII, L.P.
	Date:	 	8-12-08
	 	By:	 	InterWest Management Partners VII, LLC
its General Partner
	 	By:	 	/s/ Michael Sweeney
	 	Name:	 	Michael Sweeney
	 	Title:	 	As agent for the general
partner
	 	Interwest
Partners VII, L.P.
	Date:	 	8-12-08
	 	By:	 	InterWest Management Partners VII, LLC
its General Partner
	 	By:	 	/s/ Michael Sweeney
	 	Name:	 	Michael Sweeney
	 	Title:	 	As agent for the general
partner

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Lehman
Brothers Healthcare Venture Capital, L.P.
	Date:	 	Aug 14, 2008
	 	By:	 	Lehman Brothers HealthCare Venture Capital Associates
L.P.,
its General Partner
	 	By:	 	LB I Group Inc., its General Partner
	 	By:	 	/s/ Deborah Nordell
	 	Name:	 	Deborah Nordell
	 	Its:	 	Senior Vice President
	 	Lehman
Brothers P.A., LLC
	Date:	 	Aug 14, 2008
	 	By:	 	/s/ Deborah Nordell
	 	Name:	 	Deborah Nordell
	 	Its:	 	Senior Vice President

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Lehman
Brothers Partnership Account 2000/2001, L.P.
	Date:	 	Aug 14, 2008
	 	By:	 	LB I Group Inc., its General Partner
	 	By:	 	/s/ Deborah Nordell
	 	Name:	 	Deborah Nordell
	 	Its:	 	Senior Vice President
	 	Lehman
Brothers Offshore Partnership Account 2000/2001, L.P.
	Date:	 	Aug 14, 2008
	 	By:	 	LB I Offshore Partners Group Ltd., its General Partner
	 	By:	 	/s/ Deborah Nordell
	 	Name:	 	Deborah Nordell
	 	Its:	 	Senior Vice President

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Lilly
BioVentures, Eli Lilly & Company
	Date:	 	19 Aug 08
	 	By:	 	/s/ Darren J. Carroll
	 	By:	 	Darren J. Carroll
	 	Title:	 	Executive Director
	 	 	 	Eli Lilly and Company

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	SightLine
Healthcare Fund III, L.P.
	Date:	 	8-13-08
	 	By:	 	SightLine Healthcare Management III, LP, its GP
	 	By:	 	/s/ Maureen Harder
	 	Name:	 	Maureen Harder
	 	Title:	 	Managing Director of
SightLine Partners LLC, its GP

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	SMALLCAP
World Fund, Inc.
	Date:	 	8/22/08
	 	By:	 	Capital Research and Management Company
Its investment adviser
	 	By:	 	/s/ Michael J. Downer
	 	Name:	 	Michael J. Downer
	 	Title:	 	Vice President and
Secretary

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Versant
Affiliates Fund 1-A, L.P.

Versant Affiliates Fund 1-B, L.P.

Versant Side Fund I, L.P.

Versant Venture Capital I, L.P.
	Date:	 	8/13/08
	 	By:	 	Versant Ventures I, LLC
its General Partner
	 	By:	 	/s/ Samuel D. Colella
	 	Name:	 	Samuel D. Colella
	 	Title:	 	Managing Director

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Cross
Creek Capital, L.P.
	Date:	 	8-14-08
	 	By:	 	Cross Creek Capital GP, L.P.
its Sole General Partner
	 	By:	 	Cross Creek Capital, LLC
Its Sole General Partner
	 	By:	 	Wasatch Advisors, Inc.
Its Sole Member
	 	By:	 	/s/ Daniel Thurber
	 	Name:	 	Daniel Thurber
	 	Title:	 	Vice President

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Cross
Creek Capital Employee’s Fund, L.P.
	Date:	 	8-14-08
	 	By:	 	Cross Creek Capital GP, L.P.
Its Sole General Partner
	 	By:	 	Cross Creek Capital, LLC
Its Sole General Partner
	 	By:	 	Wasatch Advisors, Inc.
Its Sole Member
	 	By:	 	/s/ Daniel Thurber
	 	Name:	 	Daniel Thurber
	 	Title:	 	Vice President

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]

 

 

	 	 	 
	STOCKHOLDERS:
	 	 
	 

	 	 

	 	 	 	 	 	 	 
	 	Wasatch
Funds,
Inc.
Wasatch
Small Cap Growth Fund
	Date:	 	8-14-08
	 	By:	 	Wasatch Advisors, Inc.
	 	Its:	 	Investment Advisor
	 	By:	 	/s/ Daniel Thurber
	 	Name:	 	Daniel Thurber
	 	Title:	 	Vice President

[Action by Written
Consent of Stockholders of Fluidigm Corporation—Consent to
Automatic Conversion]exv10w9

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.9

 

MASTER CLOSING AGREEMENT

By and Among

FLUIDIGM CORPORATION,

a California corporation,

OCULUS PHARMACEUTICALS, INC.,

a Delaware corporation,

and

THE UAB RESEARCH FOUNDATION

dated

March 7, 2003

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	ARTICLE I DEFINITIONS	 	 	1	 
	 
	 	1.1	 	“Affiliate”	 	 	1	 
	 
	 	1.2	 	“Ancillary Documents”	 	 	2	 
	 
	 	1.3	 	“Assigned Rights”	 	 	2	 
	 
	 	1.4	 	“Cash Consideration”	 	 	2	 
	 
	 	1.5	 	“Closing”	 	 	2	 
	 
	 	1.6	 	“Closing Cash Consideration”	 	 	2	 
	 
	 	1.7	 	“Closing Date”	 	 	2	 
	 
	 	1.8	 	“Encumbrances”	 	 	2	 
	 
	 	1.9	 	“Fluidigm Series C Preferred Stock”	 	 	2	 
	 
	 	1.10	 	“License Agreement”	 	 	2	 
	 
	 	1.11	 	“New License Agreement”	 	 	2	 
	 
	 	1.12	 	“Sponsored Research Agreement”	 	 	2	 
	 
	 	1.13	 	“Technology”	 	 	2	 
	 
	 	1.14	 	“Transfer Taxes”	 	 	2	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE II TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY	 	 	3	 
	 
	 	2.1	 	Transfer of Rights and License of Technology	 	 	3	 
	 
	 	2.2	 	Excluded Assets and Liabilities	 	 	3	 
	 
	 	2.3	 	Payment	 	 	3	 
	 
	 	2.4	 	Taxes	 	 	3	 
	 
	 	2.5	 	Assigned Rights	 	 	3	 
	 
	 	2.6	 	Unassignable Rights	 	 	3	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE III THE CLOSING	 	 	4	 
	 
	 	3.1	 	The Closing	 	 	4	 
	 
	 	3.2	 	Termination of License Agreement	 	 	4	 
	 
	 	3.3	 	Agreements Between Fluidigm and UABRF	 	 	5	 
	 
	 	3.4	 	Other Documents	 	 	5	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE IV REPRESENTATIONS AND WARRANTIES OF OCULUS	 	 	5	 
	 
	 	4.1	 	Organization	 	 	5	 
	 
	 	4.2	 	Authorization	 	 	5	 
	 
	 	4.3	 	No Conflicts; Consents	 	 	5	 
	 
	 	4.4	 	Title to Assigned Rights	 	 	6	 
	 
	 	4.5	 	No Assignment	 	 	6	 
	 
	 	4.6	 	Litigation and Claims	 	 	6	 
	 
	 	4.7	 	Distribution Agreement	 	 	6	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE V REPRESENTATIONS AND WARRANTIES OF FLUIDIGM	 	 	7	 
	 
	 	5.1	 	Organization	 	 	7	 
	 
	 	5.2	 	Authorization	 	 	7	 
	 
	 	5.3	 	No Conflicts; Consents	 	 	7	 
	 
	 	5.4	 	Litigation and Claims	 	 	8	 

i

 

TABLE OF CONTENTS
 (continued)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 
	 	5.5	 	Securities Laws Exemptions	 	 	8	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE VI REPRESENTATIONS AND WARRANTIES OF UABRF	 	 	8	 
	 
	 	6.1	 	Authorization	 	 	8	 
	 
	 	6.2	 	No conflicts; Consents	 	 	8	 
	 
	 	6.3	 	Title to Technology	 	 	9	 
	 
	 	6.4	 	Litigation and Claims	 	 	9	 
	 
	 	6.5	 	Distribution Agreement	 	 	9	 
	 
	 	6.6	 	Investment Representations	 	 	10	 
	 
	 	6.7	 	Restrictions	 	 	10	 
	 
	 	6.8	 	Restrictive Legend	 	 	10	 
	 
	 	6.9	 	Notice of Proposed Transfers	 	 	11	 
	 
	 	6.10	 	Standoff Agreement	 	 	11	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE VII COVENANTS OF OCULUS	 	 	12	 
	 
	 	7.1	 	Conduct of Business	 	 	12	 
	 
	 	7.2	 	Access to Information	 	 	13	 
	 
	 	7.3	 	Regulatory Approvals	 	 	13	 
	 
	 	7.4	 	Satisfaction of Conditions Precedent	 	 	13	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE VIII COVENANTS OF UABRF	 	 	13	 
	 
	 	8.1	 	Conduct of Business	 	 	13	 
	 
	 	8.2	 	Access to Information	 	 	14	 
	 
	 	8.3	 	Regulatory Approvals	 	 	14	 
	 
	 	8.4	 	Satisfaction of Conditions Precedent	 	 	14	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE IX COVENANTS OF FLUIDIGM	 	 	14	 
	 
	 	9.1	 	Regulatory Approvals	 	 	14	 
	 
	 	9.2	 	Satisfaction of Conditions Precedent	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE X MUTUAL COVENANTS	 	 	15	 
	 
	 	10.1	 	Confidentiality	 	 	15	 
	 
	 	10.2	 	Publicity	 	 	15	 
	 
	 	10.3	 	Governmental Filings	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XI CONDITIONS TO CLOSING	 	 	15	 
	 
	 	11.1	 	Conditions to Each Party’s Obligations	 	 	15	 
	 
	 	11.2	 	Conditions to Obligations of  Oculus and UABRF	 	 	16	 
	 
	 	11.3	 	Conditions to Obligations of Fluidigm	 	 	16	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XII POST-CLOSING MATTERS	 	 	17	 
	 
	 	12.1	 	Additional Payments by Fluidigm	 	 	17	 
	 
	 	12.2	 	Settlement of Lawsuit	 	 	18	 

ii

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	ARTICLE XIII TERMINATION OF AGREEMENT	 	 	18	 
	 
	 	13.1	 	Termination by Fluidigm	 	 	18	 
	 
	 	13.2	 	Termination by UABRF	 	 	18	 
	 
	 	13.3	 	Mutual Consent	 	 	18	 
	 
	 	13.4	 	Effect of Termination	 	 	19	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XIV SURVIVAL OF REPRESENTATIONS AND WARRANTIES	 	 	19	 
	 
	 	14.1	 	Survival of Representations and Warranties	 	 	19	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XV GENERAL	 	 	19	 
	 
	 	15.1	 	Governing Law	 	 	19	 
	 
	 	15.2	 	Assignment; Binding upon Successors and Assigns	 	 	19	 
	 
	 	15.3	 	Severability	 	 	19	 
	 
	 	15.4	 	Entire Agreement	 	 	20	 
	 
	 	15.5	 	Counterparts	 	 	20	 
	 
	 	15.6	 	Expenses	 	 	20	 
	 
	 	15.7	 	Other Remedies	 	 	20	 
	 
	 	15.8	 	Amendment	 	 	20	 
	 
	 	15.9	 	Waiver	 	 	20	 
	 
	 	15.10	 	Informal  Resolution	 	 	21	 
	 
	 	15.11	 	Mediation	 	 	21	 
	 
	 	15.12	 	Notices	 	 	21	 
	 
	 	15.13	 	Construction and Interpretation of Agreement	 	 	22	 
	 
	 	15.14	 	No Joint Venture	 	 	22	 
	 
	 	15.15	 	Absence of Third Party Beneficiary Rights	 	 	22	 
	 
	 	15.16	 	Further Assurances	 	 	23	 

iii

 

EXHIBITS AND SCHEDULES

	 	 	 
	Exhibit	 	Description
	A

	 	Amended and Restated Articles of Incorporation of Fluidigm
	B

	 	Form of New License Agreement
	C

	 	Form of Sponsored Research Agreement
	D

	 	Description of Technology
	 
	 	 
	Schedule

	 	Description
	4.6

	 	Pending Litigation

iv

 

MASTER CLOSING AGREEMENT

     THIS
MASTER CLOSING AGREEMENT is entered into as of March 7, 2003 by and among FLUIDIGM
CORPORATION, a California corporation (“Fluidigm”), OCULUS PHARMACEUTICALS, INC., a Delaware
corporation (“Oculus”), and THE UAB RESEARCH FOUNDATION (“UABRF”).

RECITALS

     A. Oculus and UABRF have entered into a license agreement dated September 21,
2001 (together with all amendments and modifications thereto, the “License Agreement”)
under which Oculus was granted an exclusive license to practice the intellectual property and
technology relating to nanovolume crystallization arrays described in Schedule A to the
License Agreement.

     B. The parties hereto have entered into a binding letter agreement dated
December 19, 2002 (the “Letter Agreement”) under which Oculus and UABRF have agreed to
terminate the License Agreement, UABRF has agreed to grant to Fluidigm an exclusive license
to practice the intellectual property and technology relating to nanovolume crystallization
arrays covered by the License Agreement, and Fluidigm and UABRF have agreed to enter into a
sponsored research agreement. In exchange for the rights to be acquired by Fluidigm as
contemplated by the Letter Agreement, Fluidigm has paid cash in the amount of [***]
pursuant to the Letter Agreement and has agreed to the payment of additional cash and
securities as specified in the Letter Agreement.

     C. The parties desire to enter into this Agreement to set out additional terms and
conditions related to the closing of the transactions, and the payments to be made by
Fluidigm, contemplated by the Letter Agreement.

     NOW, THEREFORE, in consideration of the representations, warranties and agreements herein
contained, the parties agree as follows:

ARTICLE I

DEFINITIONS

     As used in this Agreement, the following terms shall have the meanings set forth or
referenced below:

     1.1 “Affiliate” of any specified person shall mean any other person directly or
indirectly controlling or controlled by or under direct or indirect common control with such
specified person. For purposes of this definition, “control” when used with respect to any
specified person means the power to direct or cause the direction of the management and policies of
such person, directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to
the foregoing.

-1-

 

     1.2 “Ancillary Documents” shall mean all documents or agreements required by this
Agreement to be executed or delivered by any party hereto.

     1.3 “Assigned Rights” shall mean any intellectual property rights owned by Oculus that
pertain in any way to the Technology, including without limitation any Inventions (as such term is
defined in Section 11 of the License Agreement) and any other patent rights and other intellectual
property rights therein owned by Oculus.

     1.4 “Cash Consideration” shall mean the sum of cash in the amount of [***] paid in
accordance with the Letter Agreement and the Closing Cash Consolidation.

     1.5 “Closing” shall mean the closing of the transactions contemplated by this
Agreement.

     1.6 “Closing Cash Consideration” shall mean cash in the amount of [***].

     1.7
“Closing Date” shall mean March 7, 2003, or such other date to which the parties
shall mutually agree in writing.

     1.8 “Encumbrances” shall mean restrictions on or conditions to transfer or assignment,
claims, liabilities, licenses, immunities from lawsuits to third parties, liens, pledges, mortgages
or security interests of any kind, whether accrued, absolute, contingent, or otherwise.

     1.9 “Fluidigm Series C Preferred Stock” shall mean the Series C Preferred Stock of
Fluidigm having the rights, preferences and privileges set forth in Fluidigm’s Articles of
Incorporation attached hereto as Exhibit A.

     1.10 “License Agreement” shall mean the license agreement between Oculus and
UABRF as described in Recital A.

     1.11 “New License Agreement” shall mean the license agreement between Fluidigm and
UABRF in the form of Exhibit B attached hereto.

     1.12 “Sponsored Research Agreement” shall mean the sponsored research agreement
between Fluidigm and UABRF in the form of Exhibit C attached hereto.

     1.13 “Technology” shall mean all intellectual property and other rights relating
to nanovolume crystallization arrays described in Exhibit D attached hereto.

     1.14
“Transfer Taxes” shall mean all sales taxes, use taxes, conveyance taxes,
transfer taxes, filing fees, recording fees, reporting fees and other similar duties, taxes and
fees, if any, imposed upon, or resulting from, the transfer of the Assigned Rights hereunder,
except federal, state or local income or similar taxes based upon or measured by revenue, income,
profit or gain from the transfer of the Assigned Rights or the operation of Oculus’ business prior
to the Closing or by any increase in the value of any of the Assigned Rights through the Closing
Date.

-2-

 

ARTICLE II

TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY

     2.1
Transfer of Rights and License of Technology. Oculus and UABRF have mutually
terminated the License Agreement as of January 30, 2003 and Oculus has surrendered all rights under
the License Agreement to UABRF. Subject to and upon the terms and conditions of this Agreement,
effective as of the Closing, Fluidigm and UABRF will enter into the New License Agreement. It is
the intent of the parties that all intellectual property rights subject to the License Agreement as
of November 27, 2002 shall be transferred and/or assigned to Fluidigm, and that all such rights
owned by UABRF shall be licensed to Fluidigm under the New License Agreement, subject to the
reservation by UABRF of certain rights as set forth in the License Agreement.

     2.2 Excluded Assets and Liabilities. Notwithstanding the provisions of Section 2.1,

(a) Fluidigm and Oculus expressly acknowledge and agree that Oculus shall not sell, transfer,
assign, convey or deliver to Fluidigm, and Fluidigm shall not purchase, acquire or accept from
Oculus, any right, title or interest of Oculus in or to any other property or assets of Oculus, and

(b) Fluidigm does not assume, and Oculus does not transfer or assign, any liabilities or
obligations, whether presently fixed and determined, contingent or otherwise, of Oculus.

     2.3 Payment. In
consideration of the execution of the New License Agreement and the
transfer of the rights thereunder, Fluidigm will deliver to UABRF the Closing Cash Consideration
and [ * * * ] shares of Fluidigm Series C
Preferred Stock valued at 2.58 per share, the price at
which Fluidigm sold and issued shares of its Series C Preferred Stock to other investors.

     2.4 Taxes. Fluidigm and Oculus shall each pay (or reimburse the other for) one-half of
all Transfer Taxes, whether imposed by law on Fluidigm and Oculus or otherwise.

     2.5 Assigned Rights. Oculus hereby sells, assigns and transfers to Fluidigm
all Assigned Rights, free and clear of all Encumbrances (except to the extent that the
settlement agreement pertaining to the Lawsuit (as such term is defined in Section 6.3) may
include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement).

     2.6 Unassignable Rights.

          (a) Notwithstanding any provision of this Agreement or any of the Ancillary Documents, but
subject to Section 11.3(c), to the extent that any of the Assigned Rights are not assignable or
otherwise transferable to Fluidigm, or if such assignment or transfer would constitute a breach
thereof or a violation of any applicable law, then neither this Agreement nor such Ancillary
Documents shall constitute an assignment or transfer (or an attempted assignment or transfer)
thereof until such consent, approval or waiver of such party or parties has been duly obtained.

          (b) If any consent required to transfer the Assigned Rights to Fluidigm has not been obtained
as of the Closing Date and Fluidigm nevertheless determines to proceed with the

-3-

 

Closing, Oculus and UABRF shall, at their own expense, continue to cooperate with Fluidigm and use
commercially reasonable efforts to obtain such consent after the Closing.

          (c) If any Assigned Right is not transferred to Fluidigm at the Closing pursuant to this
Agreement, Oculus and Fluidigm shall cooperate with each other in any reasonable arrangement
designed to provide for Fluidigm all of the benefits of such Assigned Rights. At Fluidigm’s
request, Oculus shall take all reasonable actions requested by Fluidigm to enforce for the benefit
of Fluidigm any and all rights of Oculus with respect to any such Assigned Right that is not
otherwise transferred pursuant to the provisions of this Agreement. Oculus agrees to hold in trust
for, and remit promptly to, Fluidigm all future collections or payments received by Oculus in
respect of all such Assigned Rights (net of all costs and expenses incurred by Oculus in respect
thereto); provided, however, that nothing herein shall create or provide any rights or
benefits in or to third parties.

          (d) If any intellectual property rights that are described in the New License Agreement cannot
be licensed to Fluidigm by UABRF under the New License Agreement without the consent of any third
party or without resulting in a breach or default of any agreement affecting such rights, UABRF
covenants and agrees that it shall not sue or otherwise take any legal action to restrict or
prevent Fluidigm and Fluidigm’s permitted assignees and sublicensees from practicing such
intellectual property rights as purported to be granted under the terms of the New License
Agreement.

          (e) If, subsequent to the Closing, a claim brought by any party challenging any of the
transactions contemplated hereby results in any ruling or order which has the result of frustrating
in a material way the transfer of any of the Assigned Rights hereunder to Fluidigm or the grant of
rights to Fluidigm under the New License Agreement or Fluidigm’s use thereof as provided herein,
Oculus and UABRF shall cooperate with Fluidigm in any reasonable arrangement designed to give
Fluidigm, as nearly as practicable, the same economic benefits as if such transfer or license, as
the case may be, had been consummated in accordance with the provisions hereof.

          (f) Nothing in this Section 2.6 shall be deemed to modify in any respect any of the
representations or warranties of Oculus and UABRF set forth herein or the conditions to Fluidigm’s
obligations contained in this Agreement, be deemed a waiver by Fluidigm of its right to have
received on or before the Closing Date an effective assignment of all of the Assigned Rights or be
deemed to constitute an agreement to exclude any assets from the Assigned Rights.

ARTICLE III

THE CLOSING

     3.1 The Closing. The Closing shall take place at the offices of Gray Cary Ware &
Freidenrich llp, 400 Hamilton Avenue, Palo Alto, California, at 11:00 a.m., Pacific Time,
on the Closing Date, or at such other time and place as Oculus, Fluidigm and UABRF may agree.

     3.2 Termination of License Agreement. On or before the Closing, Oculus and UABRF
shall deliver to Fluidigm an agreement and acknowledgment that the License

-4-

 

Agreement has been terminated and such other agreements and instruments as may be necessary or
appropriate to evidence the return by Oculus to UABRF of all rights under the License Agreement.

     3.3
Agreements Between Fluidigm and UABRF. At the Closing, Fluidigm and UABRF shall execute and deliver the New License Agreement and the
Sponsored Research Agreement.

     3.4 Other Documents. Each party shall deliver to the other at the Closing such other
documents, certificates, schedules, agreements and instruments required by this Agreement to
be delivered at such time.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF OCULUS 

     Oculus hereby represents and warrants to Fluidigm as follows:

     4.1 Organization. Oculus is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware and has all requisite corporate power to
own, lease and operate its properties and to conduct its business as it is currently being
conducted. Oculus is duly qualified or licensed to do business as a foreign corporation in
each jurisdiction in which the failure to be so qualified or licensed would have a material adverse
effect on Oculus.

     4.2  Authorization. This Agreement and all of the Ancillary Documents to which
Oculus is or will be a party have been, or upon their execution and delivery hereunder will have
been, duly and validly executed and delivered by Oculus and constitute, or will constitute, valid
and binding agreements of Oculus, enforceable against Oculus in accordance with their respective
terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ rights generally or by principles of public policy
or general equitable principles or the exercise of judicial discretion in accordance with such
principles. Oculus has the requisite corporate power and authority to execute and deliver this
Agreement and the Ancillary Documents to which Oculus is or will be a party and, at the time of the
Closing, will have the requisite corporate power and authority to carry out the transactions
contemplated by this Agreement and the Ancillary Documents. The execution, delivery and performance
by Oculus of this Agreement and the Ancillary Documents have been duly and validly approved and
authorized by the Board of Directors and shareholders of Oculus.

     4.3 No Conflicts; Consents. The execution and delivery by Oculus of this Agreement
and the Ancillary Documents to which Oculus is or will be a party do not, and the consummation
of the transactions contemplated hereby and thereby and compliance by Oculus with the
provisions hereof and thereof will not, contravene, conflict with, result in a breach of,
constitute a default (with or without notice or lapse of time, or both) under or violation of, or result
in the creation of any Encumbrance pursuant to, (i) any provision of the Certificate of Incorporation
or Bylaws of Oculus, (ii) any judgment, order, decree, rule, law or regulation of any court or

-5-

 

governmental authority, foreign or domestic, applicable to Oculus or to any of the Assigned Rights,
except where any such contravention, conflict, breach or default could not reasonably be expected
to have a material adverse effect on Fluidigm’s ownership of the Assigned Rights, or (iii) any
provision of any material agreement, instrument or understanding to which Oculus is a party or by
which Oculus is bound or any of the Assigned Rights are affected, except where any such
contravention, conflict, breach or default could not reasonably be expected to have a material
adverse effect on Fluidigm’s ownership of the Assigned Rights, nor will such actions give to any
other person or entity any interests or rights of any kind, including rights of termination,
acceleration or cancellation, in or with respect to any of the Assigned Rights, or result in the
creation of any Encumbrance on any of the Assigned Rights. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of Oculus to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.

     4.4 Title to Assigned Rights. Oculus has good and marketable title to all of the
Assigned Rights. All of the Assigned Rights are free and clear of any Encumbrances (except to the
extent that the settlement agreement pertaining to the Lawsuit (as such term is defined in Section
6.3) may include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement). At the Closing, Oculus will sell, convey, assign, transfer and deliver to Fluidigm
good, valid and marketable title and all right and interest in and to all of the Assigned Rights,
free and clear of any Encumbrances.

     4.5 No Assignment. Oculus has not sublicensed or otherwise transferred any material
rights under the License Agreement to any third party. As of
December 19, 2002, the License
Agreement was in full force and effect in accordance with its terms. Prior to the termination of
the License Agreement, no provisions of the License Agreement had been waived in any
material respect. Exhibit D lists all of the patent filings subject to the License
Agreement. To the knowledge of Oculus, UABRF is the owner of the patent rights within the
technology and inventions subject to the License Agreement and has not granted a license to such
technology and inventions to any person or entity other than Oculus.

     4.6 Litigation and Claims. Except as set forth on Schedule 4.6 attached hereto, there
are no claims, actions, suits, proceedings arbitrations or investigations in progress or pending
(or, to the knowledge of Oculus, threatened) before any court, tribunal or governmental agency
against Oculus that relate to any of the Assigned Rights. Oculus is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial or
arbitration proceeding with any governmental authority) with respect to any of the Assigned Rights.

     4.7 Distribution Agreement. Oculus has entered into a mutually acceptable
agreement with UABRF regarding the distribution of any and all consideration to be paid by
Fluidigm in connection with the transactions contemplated by this Agreement.

-6-

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF FLUIDIGM 

     Fluidigm hereby represents and warrants to Oculus and UABRF as follows:

     5.1 Organization. Fluidigm is a corporation duly organized, validly existing and
in good standing under the laws of the State of California and has all requisite corporate power to
own, lease and operate its properties, to conduct its business as it is currently being conducted.
Fluidigm is duly qualified or licensed to do business as a foreign corporation in each jurisdiction
in which the failure to be so qualified or licensed would have a material adverse effect on
Fluidigm.

     5.2
Authorization. This Agreement and all of the Ancillary Documents to which Fluidigm
is or will be a party have been, or upon their execution and delivery hereunder will have been,
duly and validly executed by Fluidigm and constitute, or will constitute, valid and binding
agreements of Fluidigm, enforceable against Fluidigm in accordance with their respective terms,
except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors’ rights generally or by principles of public policy or general
equitable principles or the exercise of judicial discretion in accordance with such principles.
Fluidigm has the requisite corporate power and authority to execute and deliver this Agreement and
the Ancillary Documents to which Fluidigm is or will be a party and, at the time of the Closing,
will have the requisite corporate power and authority to sell, issue and deliver the Securities
pursuant to this Agreement and to carry out the other transactions contemplated by this Agreement
and the Ancillary Documents. The execution, delivery and performance by Fluidigm of this Agreement
and the Ancillary Documents have been duly and validly approved and authorized by Fluidigm’s Board
of Directors and by all requisite action of Fluidigm’s stockholders.

     5.3
No Conflicts; Consents. The execution and delivery by Fluidigm of this Agreement
and the Ancillary Documents to which Fluidigm is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by Fluidigm with the provisions
hereof and thereof will not, contravene, conflict with, result in a breach of, constitute a default
(with or without notice or lapse of time, or both) under or violation of, or result in the creation
of any Encumbrance pursuant to, (i) any provision of the Articles of Incorporation or Bylaws of
Fluidigm, (ii) any judgment, order, decree, rule, law or regulation of any court or governmental
authority, foreign or domestic, applicable to Fluidigm except where such any such contravention,
conflict, breach or default could not reasonably be expected to have a material adverse effect on
the consummation of the transactions contemplated hereby, or
(iii) any provision of any agreement, instrument or understanding to which Fluidigm is a party or
by which Fluidigm is bound, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on the consummation of the
transactions contemplated hereby. No consent, approval, order or authorization of, or registration,
declaration or filing with, any third party or any governmental authority is required to be
obtained on the part of Fluidigm to permit the consummation of the transactions contemplated by
this Agreement or the Ancillary Documents.

-7-

 

     5.4 Litigation and Claims. There are no claims, actions, suits, proceedings,
arbitrations or investigations in progress or pending (or, to Fluidigm’s knowledge, threatened,
other than potential claims relating to the Interfering Patent (as such term is defined in Section
12.1(a) below), including, but not limited to, a possible interference) before any court, tribunal
or governmental agency, against or relating to Fluidigm, which, if determined adversely to
Fluidigm, would be likely to have a material adverse effect upon Fluidigm’s financial condition or
materially impair its ability to carry out and perform its obligations hereunder.

     5.5 Securities Laws Exemptions. Based in part on the representations of UABRF
contained in Section 6.5, the issuance of the Securities pursuant to the terms of this Agreement
will be exempt from the registration requirements of the Securities Act and the regulations
thereunder, and the registration, permit or qualification requirements of any applicable state
securities laws.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES OF UABRF

     To the best knowledge of the UABRF Director and Dr. Larry DeLucas, UABRF hereby represents to
Fluidigm as follows:

     6.1 Authorization. This Agreement and the Ancillary Documents to which UABRF is
or will be a party have been, or upon their execution and delivery hereunder will have been, duly
and validly executed and delivered by UABRF and constitute, or will constitute, valid and binding
agreements of UABRF, enforceable against UABRF in accordance with their respective terms, except as
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors’ rights generally or by principles of public policy or general equitable
principles or the exercise of judicial discretion in accordance with such principles. UABRF has
full power and authority to execute and deliver this Agreement and the Ancillary Documents to which
UABRF is or will be a party and, at the time of the Closing, will have all requisite power and
authority to carry out the transactions contemplated by this Agreement and the Ancillary Documents.
All university, foundation and other internal approvals necessary for UABRF to consummate the
transactions contemplated by this Agreement and the Ancillary Documents to which UABRF is or will
be a party have been obtained.

     6.2 No Conflicts; Consents. The execution and delivery by UABRF of this Agreement
and the Ancillary Documents to which UABRF is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by UABRF with the provisions hereof
and thereof will not, contravene, conflict with, result in a breach of, constitute a default (with
or without notice or lapse of time, or both) under or violation of, or result in the creation of
any Encumbrance pursuant to, (i) any provision of the charter documents of UABRF, (ii) any
judgment, order, decree, rule, law or regulation of any court or governmental authority, foreign or
domestic, applicable to UABRF or to the Technology, except where any such contravention, conflict,
breach or default could not reasonably be expected to have a material adverse effect on Fluidigm’s
rights under the New License Agreement or the consummation of the transactions contemplated hereby,
or (iii) any provision of any agreement, instrument or understanding to which UABRF is a party or
by which UABRF is bound or any of

-8-

 

the Technology is affected, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on Fluidigm’s rights under the
New License Agreement or the consummation of the transactions contemplated hereby, nor will such
actions give to any other person or entity any interests or rights of any kind, including rights
of termination, acceleration or cancellation, in or with respect to any of the Technology, or
result in the creation of any Encumbrance on any of the Technology. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of the UABRF to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.

     6.3 Title to Technology. UABRF is the sole owner of the technology, inventions and
patent rights in the Technology and subject to the License Agreement and has not granted a
license to such technology, inventions and patent rights to any person or entity other than
Oculus. The License Agreement has been mutually terminated by UABRF and Oculus and
neither Oculus nor any other party has any rights thereunder. UABRF has the right to grant an
exclusive license to the technology, inventions, patent rights and other rights under the New
License Agreement to Fluidigm, free and clear of any Encumbrances of any nature whatsoever,
subject to those liens, encumbrances or restrictions which may arise as a result of the
settlement of the litigation between Oculus and Syrrx, Inc. (“Syrrx”) described in Schedule 4.6
(the “Lawsuit”), provided that Syrrx shall have no rights that may be exercised after the
Closing to practice the technology, inventions, patent rights and
other rights subject to the New License Agreement, and the potential infringement by Diversified Scientific, Inc. of the Licensed IP
Rights (as such term is defined in the New License Agreement) described in Section 2.2.3 of
the New License Agreement. Exhibit D lists all of the patent filings subject to the
License Agreement. UABRF is not aware of any third-party challenges to the ownership, validity or
entitlement to priority date of any of the patent filings subject to the License Agreement or
the New License Agreement, except for the Lawsuit between Oculus and Syrrx and the settlement
agreement related to said Lawsuit provided to Fluidigm pursuant to Section 7.2 of this
Agreement.

     6.4 Litigation and Claims. Except as set forth on Schedule 4.6 attached hereto, there
are no claims, actions, suits, proceedings, arbitrations or investigations in progress or
pending (or, to the knowledge of UABRF, threatened) before any court, tribunal or governmental agency

against UABRF that relate to any of the Technology. UABRF is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial
or arbitration proceeding with any governmental authority) with respect to any of the Technology,
except to the extent that UABRF may be deemed to be a party thereto as a result of UABRF’s
status as a shareholder of Oculus and having a member on the Board of Directors of Oculus as
well as the status of Dr. Larry DeLucas as a member of the Board of Directors of Oculus and a
shareholder of Oculus.

     6.5 Distribution Agreement. UABRF has entered into a mutually acceptable
agreement with Oculus regarding the distribution of any and all consideration to be paid
by Fluidigm in connection with the transactions contemplated by this Agreement.

-9-

 

     6.6 Investment Representations

          (a) UABRF is acquiring the shares of Fluidigm capital stock to be issued
hereunder (the “Securities”) for investment and not with the view to the public resale
or distribution thereof, and UABRF has no present intention of selling, granting any
participation in, or otherwise distributing the Securities, other than in accordance with the terms of a
Termination Agreement dated as of ____, 2003 between UABRF and Oculus.
UABRF understands that the Securities have not been registered under the Securities Act by reason
of a specific exemption thereunder, which depends upon, among other things, the bona fide nature of
UABRF’s investment intent as expressed herein.

          (b) UABRF acknowledges that the Securities must be held indefinitely unless they are
subsequently registered under the Securities Act or Fluidigm receives an opinion of counsel
satisfactory to Fluidigm that such registration is not required. UABRF is aware of the provisions
of Rule 144 promulgated under the Securities Act which permit limited resale of stock purchased in
a private placement subject to the satisfaction of certain conditions.

          (c) UABRF understands that no public market now exists for the Securities and that there can
be no assurance that a public market will ever exist for the Securities.

          (d) UABRF is an “accredited investor” as defined in the Securities Act, and has such knowledge
and experience in financial and business matters that it is capable of evaluating the merits and
risks of the investment in the Securities.

          (e) UABRF has been given the opportunity to obtain any information or documents related to,
and ask questions and receive answers about Fluidigm and its business, prospects and risks which
UABRF deems necessary, to evaluate the merits and risks related to UABRF’s investment in the
Securities and to verify the information UABRF received.

          (f) UABRF’s financial condition is such that it can afford to bear the economic risk of
holding the Securities for an indefinite period of time, and it has adequate means of providing for
its current needs and contingencies and to suffer a complete loss of its investment in such
Securities.

     6.7 Restrictions. No Securities shall be sold, assigned, transferred or pledged except
upon the conditions specified in this Agreement. UABRF will cause any proposed purchaser, assignee,
transferee or pledgee of the Securities to agree in writing to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement.

     6.8 Restrictive Legend. Each certificate representing the Securities shall (unless
otherwise permitted by the provisions of Section 6.9 below) be stamped or otherwise imprinted with
a legend in the following form (in addition to any legend required under applicable state
securities laws):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”). SUCH

-10-

 

SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE
OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF
COUNSEL (WHICH MAY BE COUNSEL FOR THE COMPANY) OR OTHER EVIDENCE
REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS
EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF THE SECURITIES ACT.”

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET
STAND-OFF AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH
IS ON FILE WITH THE SECRETARY OF THE COMPANY.”

     UABRF consents to Fluidigm making a notation on its records and giving instructions to any
transfer agent of the Securities in order to implement the restrictions on transfer established in
Sections 6.7 through 6.10 of this Agreement.

     6.9 Notice of Proposed Transfers. UABRF and any transferee of any certificate
representing the Securities, by acceptance thereof, agrees to comply in all respects with the
restrictions on transfer contained in Sections 6.7 through 6.10 of this Agreement. Prior to any
proposed sale, assignment, transfer or pledge of any Securities (other than any transfer not
involving a change in beneficial ownership), unless there is in effect a registration statement
under the Securities Act covering the proposed transfer, the holder thereof shall give written
notice to Fluidigm of such holder’s intention to effect such transfer, sale, assignment or pledge.
Each such notice shall describe the manner and circumstances of the
proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder’s expense by
either (i) a written opinion of legal counsel who shall, and whose legal opinion shall be,
reasonably satisfactory to Fluidigm, addressed to Fluidigm, to the effect that the proposed
transfer of the Securities may be effected without registration under the Securities Act, or (ii) a
“no action” letter from the Securities and Exchange Commission (the “Commission”) to the effect
that the transfer of such Securities without registration will not result in a recommendation by
the staff of the Commission that action be taken with respect thereto, or (iii) any other evidence
reasonably satisfactory to counsel to Fluidigm, whereupon the holder of such Securities shall be
entitled to transfer such Securities in accordance with the terms of the notice delivered by the
holder to Fluidigm; provided, however, that no such legal opinion, “no action” letter or other
evidence shall be required with respect to a transfer to an affiliate of the holder. Each
certificate evidencing the Securities transferred as above provided shall bear, except if such
transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 6.8
above, except that such certificate shall not bear such restrictive legend if, in the opinion of
counsel for such holder and Fluidigm, such legend is not required in order to establish compliance
with any provisions of the Securities Act or this Agreement.

     6.10 Standoff Agreement. UABRF agrees in connection with Fluidigm’s initial sale of
securities pursuant to an effective registration statement, upon notice by Fluidigm or the
underwriters managing such offering, not to sell, make any short sale of, loan, pledge (or

-11-

 

otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or
indirectly dispose of any Securities (other than those included in the registration) without the
prior written consent of Fluidigm and such managing underwriters for such period of time as
Fluidigm’s Board of Directors establishes pursuant to its good faith negotiations with such
managing underwriters; provided, however that:

               (i) such agreement shall not exceed one hundred eighty (180) days;

               (ii) such agreement shall not apply to transfers to an affiliate, provided that such
affiliate agrees to be bound by the terms of such agreement, to the same extent as if such
transferee were the original party thereunder;

               (iii) UABRF shall not be subject to such agreement unless (A) all executive officers and
directors of Fluidigm, (B) all shareholders of Fluidigm holding more than 1% of Fluidigm’s
outstanding capital stock and (C) all holders of registration rights, are subject to or obligated
to enter into similar agreements; and

               (iv) if and when any person identified in clause (iii) is released, in whole or in part,
from such agreement (whether or not such release is contemplated at the time of the offering) or if
any such agreement is terminated, UABRF shall be concurrently released on a pro rata basis based on
the number of Securities held by such person and UABRF.

          (b) UABRF agrees that prior to the initial public offering it will not transfer
securities of Fluidigm unless each transferee agrees in writing to be bound by all of the
provisions of this Section 6.10, provided that this Section 6.10 shall not apply to transfers
pursuant to a registration statement.

     UABRF hereby consents to the placement of stop transfer orders with Fluidigm’s transfer agent
in order to enforce the foregoing provision and agrees to execute a market standoff agreement with
said underwriters in customary form consistent with the provisions of this Section 6.10.

ARTICLE VII

COVENANTS OF OCULUS

     7.1 Conduct of Business. During the period from the date of this Agreement to the
Closing, Oculus will conduct its business in the ordinary course consistent with past
practices. During the period from the date of this Agreement to the Closing, Oculus will not
without the prior written consent of Fluidigm:

          (a) encumber or permit to be encumbered any of the Technology or Assigned Rights;

          (b) dispose of any of the Technology or Assigned Rights;

          (c) waive or release any right or claim relating to any Technology or Assigned Rights; or

-12-

 

          (d) agree to do any of the things described in the preceding clauses of this Section 7.1.

Fluidigm agrees that the foregoing restrictions will not prevent Oculus from entering into a
settlement agreement with Syrrx to settle the Lawsuit, provided that such settlement does not
involve the sale, transfer or assignment of the Technology or the Assigned Rights, or any rights in
any of the foregoing, or result in the creation of any Encumbrance on the Technology, the Assigned
Rights, or any rights in any of the foregoing.

     7.2 Access to Information. Until the earlier of the termination of this Agreement or
the Closing, Oculus will allow Fluidigm and its agents reasonable access upon reasonable notice and
during normal working hours to its files, books, records, and offices relating to the Technology
and Assigned Rights, except where prohibited by contract or protected by privilege. In furtherance
of the above, Fluidigm and its counsel and advisors shall have reasonable access during normal
business hours to pertinent contracts of Oculus, including an unsigned final version of the
settlement agreement between Oculus and Syrrx related to the Lawsuit, and drafts of such settlement
agreement (to the extent it is permissible under applicable confidentiality terms and with the
understanding that Oculus may be required to obtain the return or destruction by Fluidigm of the
final version and drafts of such settlement agreement prior to its execution), as well as all
scientific notebooks, invention records and other documents related to the conception and reduction
to practice and prosecution of the patent filings listed on
Exhibit D, including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations and
research related to the Technology, the License Agreement and the New License Agreement.

     7.3 Regulatory Approvals. Prior to the Closing, Oculus will execute and file, or join
in the execution and filing of, any application or other document that may be reasonably necessary
in order to obtain the authorization, approval or consent of any governmental entity that may be
required in connection with the consummation of the transactions contemplated by this Agreement.
Oculus will use commercially reasonable efforts to obtain all such authorizations, approvals and
consents.

     7.4
Satisfaction of Conditions Precedent. Oculus will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transactions contemplated hereby.

ARTICLE VIII

COVENANTS OF UABRF

     8.1 Conduct of Business. During the period from the date of this Agreement to
the Closing, UABRF will not without the prior written consent of Fluidigm:

          (a) encumber or permit to be encumbered any of the Technology;

-13-

 

          (b) dispose
of any of the Technology;

          (c) waive or release any right or claim relating to any Technology; or

          (d) agree to do any of the things described in the preceding clauses of this
Section 8.1.

Fluidigm agrees that the foregoing restrictions will not prevent UABRF from consenting to a
settlement agreement between Oculus and Syrrx to settle the Lawsuit, provided that such
settlement does not involve the sale, transfer or assignment of the Technology or the
Assigned Rights, or any rights in any of the foregoing, or result in the creation of any
Encumbrance on the Technology, the Assigned Rights, or any rights in any of the foregoing.

     8.2 Access to Information. Until the earlier of the termination of this
Agreement or the Closing, UABRF will allow Fluidigm and its agents reasonable access upon
reasonable notice and during normal working hours to its files, books, records, and offices
relating to the Technology and Assigned Rights, except where prohibited by contract or
protected by privilege. In furtherance of the above, Fluidigm and its counsel and advisors
shall have reasonable access during normal business hours to pertinent scientific notebooks,
invention records and other documents related to the conception and reduction to practice
and prosecution of the patent filings listed on Exhibit D, including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations
and research related to the Technology, the License Agreement and the New License Agreement.

     8.3 Regulatory Approvals. Prior to the Closing, UABRF will execute and file, or
join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity
that may be required in connection with the consummation of the transactions contemplated by
this Agreement. UABRF will use commercially reasonable efforts to obtain all such
authorizations, approvals and consents.

     8.4 Satisfaction of Conditions Precedent. UABRF will use commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing
hereunder, and to cause the transactions contemplated hereby to be consummated, and, without
limiting the generality of the foregoing, to obtain all consents and authorizations of third parties
and to make all filings with, and give all notices to, third parties which may be necessary or
reasonably required on its part in order to effect the transactions contemplated hereby.

ARTICLE IX

COVENANTS OF FLUIDIGM

     9.1 Regulatory Approvals. Prior to the Closing, Fluidigm will execute and
file, or join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any
governmental entity that may be required in connection with the consummation of the
transactions contemplated by this Agreement. Fluidigm will use its commercially reasonable
efforts to obtain all such authorizations, approvals and consents.

-14-

 

     9.2 Satisfaction of Conditions Precedent. Fluidigm will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transaction contemplated hereby.

ARTICLE X

MUTUAL COVENANTS

     10.1 Confidentiality. The parties acknowledge that the Confidential Disclosure
Agreement dated as of October 8, 2002 between Fluidigm and Oculus and the Confidential Disclosure
Agreement dated December 19, 2002 between Fluidigm, Oculus and UABRF are binding upon the parties
hereto and in full force and effect, except to the extent that the provisions hereof supersede
provisions to similar effect contained in the Confidential Disclosure Agreements. The terms of the
Confidential Disclosure Agreements (exclusive of such superseded provisions) are incorporated in
this Agreement by this reference.

     10.2 Publicity. Except as may otherwise be required by law, none of the parties hereto
shall make or cause to be made any public announcements in respect of this Agreement or the
transactions contemplated herein or otherwise communicate with any news media without the prior
written consent of the other party, provided, however, that following the Closing Fluidigm may
issue a press release to announce the closing of the transactions contemplated hereby and the
execution and delivery of the New License Agreement and Sponsored Research Agreement with UABRF
provided that such press release shall not be issued prior to the execution by Syrrx
of a settlement agreement with Oculus to settle the litigation described in Schedule 4.6 but in any
event the press release may be issued no later than 30 days from the execution date of the New
License Agreement. Except for the press release issued by Fluidigm, none of the parties hereto will
make any public disclosure prior to the Closing or with respect to the Closing unless all parties
agree on the text and timing of such public disclosure, except as required by law. Nothing
contained in this Section shall prevent any party at any time from furnishing any information
pursuant to the requirements of any governmental entity; provided, however, that
if such party is required to furnish such information, it will provide a copy to the other parties.

     10.3 Governmental Filings. As promptly as practicable after the execution of this
Agreement, each party shall make any and all governmental filings required with respect to the
transactions contemplated in this Agreement and the Ancillary Documents.

ARTICLE XI

CONDITIONS TO CLOSING

     11.1 Conditions to Each Party’s Obligations. The respective obligations of each party
to effect the transactions to be performed by such party at the Closing are subject to the
satisfaction at or prior to the Closing of the following conditions any of which may be waived in
writing by each party:

-15-

 

          (a) No order shall have been entered, and not vacated, by a court or administrative agency
of competent jurisdiction, in any action or proceeding which enjoins, restrains or prohibits the
sale of the Assigned Rights, the grant of rights under the New License Agreement or the
consummation of any other transaction contemplated hereby.

          (b) All permits, authorizations, approvals and orders required to be obtained under all
applicable statutes, codes, ordinances, rules and regulations in connection with the transactions
contemplated hereby shall have been obtained and shall be in full force and effect at the Closing
Date.

          (c) There shall be no litigation pending or threatened by any regulatory body or private
party in which (i) an injunction is or may be sought against the transactions contemplated hereby,
or (ii) relief is or may be sought against any party hereto as a result of this Agreement and in
which, in the good faith judgment of the Board of Directors of either Fluidigm, Oculus or UABRF
(relying on the advice of their respective legal counsel), such regulatory body or private party
has the probability of prevailing and such relief would have a material adverse affect upon such
party.

     11.2 Conditions to Obligations of Oculus and UABRF. The obligations of Oculus and UABRF
to effect the transactions to be performed by Oculus and UABRF at the Closing are subject to the
satisfaction at or prior to the Closing of the following additional conditions any of which may be
waived in writing by Oculus and UABRF:

          (a) All of the representations and warranties of Fluidigm set forth in Article V hereof
shall be true in all material respects on and as of the Closing Date with the same force and effect
as if they had been made at the Closing, except for changes contemplated by this Agreement.

          (b) All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Fluidigm at or prior to the Closing shall have been duly complied with and performed
in all material respects.

     11.3 Conditions to Obligations of Fluidigm. The obligations of Fluidigm to effect the
transactions to be performed by it at the Closing are subject to the satisfaction at or prior to
the Closing of the following additional conditions any of which may be waived in writing by
Fluidigm:

          (a) All of the representations and warranties of Oculus and UABRF set forth in Articles IV
and VI hereof shall be true in all material respects on and as of the Closing Date with the same
force and effect as if they had been made at the Closing, except for changes contemplated by this
Agreement.

          (b) All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Oculus and UABRF at or prior to the Closing shall have been duly complied with and
performed in all material respects.

          (c) All required consents from third parties required to allow the consummation of the sale
of the Assigned Rights, the grant of rights under the New License

-16-

 

Agreement and the other transactions contemplated hereby shall have been obtained and delivered to
Fluidigm.

          (d) Fluidigm shall have received an opinion from the attorney(s) prosecuting the patent
filings listed on Exhibit D, in form and substance reasonably acceptable to Fluidigm, as to
the following matters: (i) assignments of the inventions covered by the patent filings to UABRF
have been properly filed with the United States Patent and Trademark Office (“USPTO”), (ii) UABRF
is named as the sole owner of the inventions covered by the patent filings listed on Exhibit
D, (iii) a declaration of interference was timely requested with at least one of the pending
U.S. patent applications listed on Exhibit D and U.S. Patent No. 6,296,673 with the USPTO
in accordance with U.S.C. Section 135, (iv) none of the patents listed on Exhibit D have
been held to be permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and none of the patents listed on Exhibit D have been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, and (v) the patent applications listed on
Exhibit D were filed in good faith and have not been abandoned or finally disallowed
without the possibility of appeal or refiling of such application.

ARTICLE XII

POST-CLOSING MATTERS

     12.1 Additional Payments by Fluidigm. In addition to the consideration delivered by
Fluidigm at the Closing, Fluidigm will pay the following amounts to UABRF upon the achievement of
the following milestones:

          (a)
Milestone 1. Milestone 1 shall be satisfied
upon a declaration by the USPTO of an interference between a pending patent
application in the Technology and U.S. Patent No. 6,296,673 (the “Interfering Patent). Within
thirty (30) days after
Fluidigm receives written notice of the USPTO declaration of interference, Fluidigm will issue shares of its stock having a
value of $600,000 (based on the fair value of the stock at the time Milestone 1 is achieved),
subject to compliance with applicable securities laws.

          (b)
Milestone 2. Milestone 2 shall be satisfied upon the achievement of freedom to
operate (as specified below) with respect to relevant claims in the Interfering Patent for
Fluidigm’s Topaz3 crystallization microprocessor, as determined by Fluidigm in
its sole discretion that either (i) a U.S. patent has issued from an application listed on
Exhibit D or subsequent applications claiming priority thereto with claims that the USPTO
has determined are entitled to priority in view of claims in the Interfering Patent and which
claims cover the Topaz crystallization microprocessor, or (ii) a cross-license for the Technology
has been signed by Fluidigm and a third party controlling the Interfering Patent and related
applications such that the interference is terminated and Fluidigm has freedom to operate with
respect to the Interfering Patent and related filings. Within thirty (30) days after
such determination by Fluidigm, Fluidigm will issue shares of its
stock having a value of $1,500,000
(based on the fair value at the time Milestone 2 is achieved), subject to compliance with
applicable securities laws. In addition,
(i) Fluidigm will enter into a non-transferable site license with
Athersys, Inc.

-17-

 

(“Athersys”) under which Athersys will have the right to use the Technology
 for internal drug efforts, but not to provide service or equipment
 to third parties.

          (c) Stock to
be Issued. If Fluidigm is a private company at the time a milestone is
achieved, upon achievement of a milestone Fluidigm will issue shares of the series of Fluidigm
Preferred Stock that was issued in Fluidigm’s most recent financing and the shares will be valued
at the price at which the shares were sold in such financing. If Fluidigm is a public company at
the time a milestone is achieved, upon achievement of a milestone Fluidigm will issue shares of
Fluidigm Common Stock and the shares will be valued at the average closing price of Fluidigm’s
Common Stock over the five trading days preceding the achievement of the milestone.

     12.2
Settlement of Lawsuit. If the Lawsuit has not been settled or dismissed as of the
Closing Date:

          (a) Oculus agrees that Fluidigm and its counsel and advisors shall have reasonable access
during normal business hours to the final version of the settlement agreement between Oculus and
Syrrx related to the Lawsuit, and drafts of such settlement agreement (to the extent permissible
under applicable confidentiality terms), in the manner contemplated by Section 7.2 of this
Agreement, until the Lawsuit is settled or dismissed.

          (b) Oculus and UABRF agree that if a settlement agreement related to the Lawsuit is entered
into after the Closing Date, the settlement will not involve the sale, transfer or assignment of
the Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the
creation of any Encumbrance on the Technology, the Assigned Rights, or any rights in any of the
foregoing.

ARTICLE XIII

TERMINATION OF AGREEMENT

     13.1 Termination by Fluidigm. This Agreement may be terminated at any time before the
Closing by action of the Board of Directors of Fluidigm upon written notice to Oculus and UABRF,
specifying the basis for such termination, if (i) Oculus or UABRF shall have breached in any
material respect any of their covenants or agreements contained in this Agreement, or (ii) any
representation or warranty of Oculus or UABRF contained in this Agreement shall have been
materially inaccurate.

     13.2 Termination by UABRF. This Agreement may be terminated at any time before the
Closing by action of the Board of Directors or other governing body of UABRF upon written notice to
Fluidigm, specifying the basis for such termination, if (i) Fluidigm shall have breached in any
material respect any of its covenants or agreements contained in this Agreement, or (ii) any
representation or warranty of Fluidigm contained in this Agreement shall have been materially
inaccurate.

     13.3 Mutual Consent. This Agreement may be terminated at any time before the Closing,
by the mutual written consent of Fluidigm, Oculus and UABRF.

-18-

 

     13.4
Effect of Termination. Upon any termination of this Agreement, all parties hereto
shall be relieved of all further obligations under this Agreement, except for the provisions of
Section 2.5 regarding the assignment by Oculus to Fluidigm of Assigned Rights, together with all
patent rights and all other intellectual property rights therein, Section 15.6 regarding the
payment of certain expenses and Section 10.1 regarding the continuing obligations of the parties
under the Confidential Disclosure Agreements.

ARTICLE XIV

SURVIVAL OF REPRESENTATIONS AND WARRANTIES

     14.1 Survival of Representations and Warranties. The representations and warranties set forth
in this Agreement shall survive the Closing for a period equal to the greater of 12 months after
the Closing Date or the date on which both Milestones specified in Section 12.1 have been achieved.
After the expiration of such period, such representations and warranties shall expire and be of no
further force and effect.

ARTICLE XV

GENERAL

     15.1
Governing Law. It is the intention of the parties hereto that the internal laws of
the State of California (irrespective of its choice of law principles) shall govern the validity of
this Agreement, the construction of its terms, and the interpretation and enforcement of the rights
and duties of the parties hereto; provided, however, that any disputes involving UABRF shall be
governed by the internal laws of the State of Alabama (irrespective of its choice of law principles
and any disputes involving UABRF shall be resolved Birmingham, Alabama in accordance with the
provisions of Section 15.11 and UABRF shall have the right to raise all of the defenses available
to the University of Alabama at Birmingham.

     15.2
Assignment; Binding upon Successors and Assigns. None of the parties hereto may
assign any of its rights or obligations hereunder (whether by operation of law or otherwise)
without the prior written consent of the other party; provided, however, that any party may assign
its rights and obligations under covenants and agreements to be performed after the Closing in
connection with the sale of all or substantially all of such party’s business. This Agreement will
be binding upon and inure to the benefit of the parties hereto and their respective permitted
successors and assigns.

     15.3
Severability. If any provision of this Agreement, or the application thereof,
becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable,
the remainder of this Agreement will continue in full force and effect and the application of such
provision to other persons or circumstances shall be interpreted so as best to reasonably effect
the intent of the parties hereto. The parties further agree to replace such illegal, void or
unenforceable provision of this Agreement with a valid and enforceable provision which will
achieve, to the extent possible, the economic, business and other purposes of the illegal, void or
unenforceable provision.

-19-

 

     15.4 Entire Agreement. This Agreement (including the Exhibits and Schedules hereto) the
Ancillary Agreements, the documents and instruments and other agreements among the parties hereto
referenced herein and therein, and the exhibits thereto, constitute the entire understanding and
agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede
all prior and contemporaneous agreements or understandings, inducements or conditions, express or
implied, written or oral, between the parties with respect hereto and thereto including, without
limitation, the Letter Agreement. To the extent that any provision of this Agreement conflicts with
any provision of the New License Agreement or the Sponsored Research Agreement between Fluidigm and
UABRF, the applicable provision of the New License Agreement or the Sponsored Research Agreement,
as the case may be, shall control and supersede the applicable provision of this Agreement.

     15.5 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall constitute an original and all of which together shall constitute one and the same
instrument.

     15.6 Expenses.

          (a) The parties shall each pay their own legal, accounting and financial advisory fees and
other out-of-pocket expenses incurred incident to the negotiation, preparation and carrying out of
this Agreement and the transactions herein contemplated, whether or not the transactions
contemplated hereby are consummated.

          (b) Each party shall indemnify the other against, and agrees to hold the other harmless from,
all liabilities and expenses (including reasonable attorneys’ fees) in connection with
any claim by any person for compensation as a broker, finder or in any similar capacity, by
reason of services allegedly rendered to the indemnifying party in connection with the
transactions contemplated hereby.

     15.7 Other Remedies. Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party shall be deemed cumulative with and not exclusive of any other
remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not
preclude the exercise of any other.

     15.8 Amendment. Any term or provision of this Agreement may be amended by a written
instrument signed by Fluidigm, Oculus and UABRF; provided that any term or provision that pertains
only to UABRF and Fluidigm may be amended by a written instrument signed by UABRF and Fluidigm.

     15.9 Waiver. Any party hereto may, by written notice to the other party: (i) waive any
of the conditions to its obligations hereunder or extend the time for the performance of any of the
obligations or actions of another party; (ii) waive any inaccuracies in the representations of
another party contained in this Agreement or in any documents delivered pursuant to this Agreement;
(iii) waive compliance with any of the covenants of the other contained in this Agreement; or (iv)
waive or modify performance of any of the obligations of another party. Except as specifically
contemplated by this Agreement, no action taken pursuant to this Agreement, including without
limitation any investigation by or on behalf of any party, shall be

-20-

 

deemed to constitute a waiver by the party taking such action of compliance with any
representation, warranty, condition or agreement contained herein. Waiver of the breach of any one
or more provisions of this Agreement shall not be deemed or construed to be a waiver of other
breaches or subsequent breaches of the same provisions.

     15.10
Informal Resolution. In the event of any controversy or claim arising under this
Agreement, officers or comparable officials of UABRF, Oculus and Fluidigm shall promptly meet and
attempt in good faith to reach a resolution of such controversy or claim.

     15.11
Mediation. Any controversy or claim between any of the parties hereto arising out
of or relating to this Agreement that is not resolved by the parties within thirty (30) days after
delivery of notice of such controversy or claim, upon written notice of either Fluidigm, Oculus or
UABRF, shall be submitted for resolution by mediation in accordance with commercial mediation
guidelines. Any mediation proceeding shall be conducted in the County of Cook, City of Chicago, in
the State of Illinois. The mediation shall be concluded within a ninety (90) day period after
notice.

     15.12
Notices. All notices and other communications hereunder will be in writing and will
be deemed given (i) upon receipt if delivered personally (or if mailed by registered or certified
mail), (ii) the next business day after dispatch if sent by overnight delivery
service, (iii) upon dispatch if transmitted by facsimile (and confirmed by a copy delivered in
accordance with clause (i) or (ii)), properly addressed to the parties at the following addresses:

	 	 	 	 	 
	 
	 	Fluidigm:
	 	Fluidigm Corporation
	 
	 	 	 	7100 Shoreline Court
	 
	 	 	 	South San Francisco, CA 94080
	 
	 	 	 	Attention:  President
	 
	 	 	 	Facsimile No.: (650) 871-7192
	 
	 	 	 	 
	 
	 	with a copy to:
	 	Fluidigm Corporation
	 
	 	 	 	7100 Shoreline Court
	 
	 	 	 	South San Francisco, CA 94080
	 
	 	 	 	Attention: General Counsel
	 
	 	 	 	Facsimile No.: (650) 871-7195
	 
	 	 	 	 
	 
	 	Oculus:
	 	Oculus Pharmaceuticals, Inc.
	 
	 	 	 	1601 12th Avenue South
	 
	 	 	 	Birmingham, AL 35205
	 
	 	 	 	Attention: B.J. Lehman
	 
	 	 	 	Facsimile No: (216) 361-9495
	 
	 	 	 	 
	 
	 	 	 	and
	 
	 	 	 	 
	 
	 	 	 	Oculus Pharmaceuticals, Inc.
	 
	 	 	 	3201 Carnegie Avenue
	 
	 	 	 	Cleveland, OH 44115
	 
	 	 	 	Attention: B.J. Lehman
	 	 	 	 	Facsimile No.: (216) 361-9495

-21-

 

	 	 	 	 	 
	 	 	 	 	 
	 	 	UABRF:
	 	The UAB Research Foundation
	 	 	 	 	1120G Administration Building
	 	 	 	 	701 20th Street South
	 	 	 	 	Birmingham, AL 35294-0111
	 	 	 	 	Attention: Director
	 	 	 	 	Facsimile No.: (205) 975-5560

     Any party may change its address for such communications by giving notice thereof to the other
party in conformity with this Section.

     15.13 Construction and Interpretation of Agreement.

          (a) This Agreement has been negotiated by the parties hereto and their respective attorneys,
and the language hereof shall not be construed for or against any party.

          (b) The titles and headings herein are for reference purposes only and shall not in any
manner limit the construction of this Agreement, which shall be considered as a
whole.

          (c) Any reference to a “material adverse effect” with respect to any entity or group of
entities means a material adverse effect on the business, assets (including intangible assets),
financial condition, properties, liabilities, results of operations or prospects of such entity.

          (d) Any reference to a party’s “knowledge means such party’s actual
knowledge after reasonable inquiry of its directors, officers and other management level employees
that have responsibility for the referenced matters.

          (e) When reference is made to a Section or Article, such reference shall be to a Section or
Article of the Agreement, unless otherwise indicated.

     15.14 No Joint Venture. Nothing contained in this Agreement shall be deemed or construed
as creating a joint venture or partnership between any of the parties hereto. No party is by virtue
of this Agreement authorized as an agent, employee or legal representative of any other party. No
party shall have the power to control the activities and operations of any other and their status
is, and at all times, will continue to be, that of independent contractors with respect to each
other. No party shall have any power or authority to bind or commit any other. No party shall hold
itself out as having any authority or relationship in contravention of this Section.

     15.15 Absence of Third Party Beneficiary Rights. No provisions of this Agreement are
intended, nor shall be interpreted, to provide or create any third party beneficiary rights or any
other rights of any kind in any client, customer, affiliate, shareholder, partner of any party
hereto or any other person or entity unless specifically provided otherwise herein, and, except as
so provided, all provisions hereof shall be personal solely between the parties to this Agreement.

-22-

 

     15.16 Further Assurances. In connection with this Agreement and the transactions
contemplated hereby, each party shall execute and deliver any additional documents and instruments
and perform any additional acts that may be reasonably necessary or appropriate to effectuate and
perform the provisions of this Agreement and such transactions and the intention of the parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

-23-

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth
above.

	 	 	 	 	 	 	 
	 	 	FLUIDIGM CORPORATION	 	 
	 	 	 	 	 	 	 
	 	 	By:
	 	/s/ Gajus Worthington	 	 
	 	 	 	 	 	 	 
	 
	 	 	Title:	President & CEO	 
	 	 	 	 	 	 	 
	 	 	OCULUS PHARMACEUTICALS, INC.	 	 
	 	 	 	 	 	 	 
	 	 	By:
	 	/s/ (ILLEGIBLE)	 	 
	 	 	 	 	 	 	 
	 
	 	 	Title:	President & CEO	 
	 	 	 	 	 	 	 
	 	 	THE UAB RESEARCH FOUNDATION	 	 
	 	 	 	 	 	 	 
	 	 	By:
	 	/s/ (ILLEGIBLE)	 	 
	 	 	 	 	 	 	 
	 
	 	 	Title:	Director	 

	 	 	 
	Acknowledged and agreed to	 	 
	this March 7, 2003.	 	 
	 	 	 
	/s/ Dr. Larry DeLucas
 
	 	 
	Dr. Larry DeLucas	 	 

-24-

 

SCHEDULE 4.6

Lawsuit filed by Syrrx, Inc. against Oculus on April 30, 2002 in the United States District Court
for the District of Delaware — Syrrx and Oculus may enter into a settlement agreement to settle the
Lawsuit prior to the Closing under the Agreement; as part of the settlement a judgment or other
order will be entered against Oculus by the court in which the Lawsuit was filed.

 

 

EXHIBIT A

Amended and Restated

Articles of Incorporation of Fluidigm

Superseded by Exhibit 3.1 filed with Registration Statement on April 14, 2008.

 

 

AMENDED AND RESTATED

ARTICLES OF INCORPORATION OF

FLUIDIGM CORPORATION

     Gajus V. Worthington and William Smith certify that:

     1. They are the President and Secretary, respectively, of Fluidigm Corporation, a California
corporation (the “Corporation”).

     2. The Articles of Incorporation of the Corporation are amended and restated in full to read
as set forth in EXHIBIT A attached hereto.

     3. Said Amended and Restated Articles of Incorporation have been duly approved by the
Corporation’s Board of Directors.

     4. Said Amended and Restated Articles of Incorporation have been duly approved by the required
vote of shareholders in accordance with Sections 902 and 903 of the Corporations Code. The total
number of outstanding shares of the corporation is 8,363,318 shares of Common Stock, 2,727,273
shares of Series A Preferred Stock, 6,460,675 shares of Series B Preferred Stock and 16,364,832
shares of Series C Preferred Stock. The number of shares voting in favor of the amendment equaled
or exceeded the vote required. The percentage vote required was more than 50% of the outstanding
Common Stock, voting as a single class, more than 66 2/3% of the outstanding Series C Preferred
Stock, voting as a single class, more than 66 2/3% of the outstanding Preferred Stock voting as a
single class and more than 50% of the outstanding Common Stock and Preferred Stock, voting together
as a single class.

     I further declare under penalty of perjury that the matters set forth in the foregoing
certificate are true and correct of my own knowledge.

     Executed at Palo Alto, California, this 17th day of December, 2003.

	 	 	 	 	 
	 	 	 
	 	                                                  /s/  Gajus V. Worthington
 	 
	 	Gajus V. Worthington 	 
	 	President 	 
	 
	 	 	 
	 	                                                    /s/ William Smith
 	 
	 	William Smith 	 
	 	Secretary 	 
	 

 

 

Exhibit A

AMENDED AND RESTATED

ARTICLES OF INCORPORATION OF

FLUIDIGM CORPORATION

ARTICLE I

     The name of the corporation is Fluidigm Corporation.

ARTICLE II

     The purpose of this corporation is to engage in any lawful act or activity for which a
corporation may be organized under the General Corporation Law of California other than the banking
business, the trust company business or the practice of a profession permitted to be incorporated
under the California Corporations Code.

ARTICLE III

     The total number of shares of stock that the corporation shall have authority to issue is One
Hundred Nine Million One Hundred Twenty-Six Thousand Eight Hundred Twenty-Seven (109,126,827),
consisting of Sixty-Five Million Five Hundred Thousand (65,500,000) shares of Common Stock, $0.001
par value per share, and Forty-Three Million Six Hundred Twenty-Six Thousand Eight Hundred
Twenty-Seven (43,626,827) shares of Preferred Stock, $0.001 par value per share. The first series
of Preferred Stock shall be designated “Series A Preferred Stock” and shall consist of Two Million
Seven Hundred Twenty–Seven Thousand Two Hundred Seventy–Three (2,727,273) shares. The second
series of Preferred Stock shall be designated “Series B Preferred Stock” and shall consist of Six
Million Four Hundred Sixty Thousand Six Hundred Seventy-Five (6,460,675) shares. The third
series of Preferred Stock shall be designated “Series C Preferred Stock” and shall consist of
Twenty Million Five Hundred Fifty-One Thousand One Hundred Sixty Three (20,551,163) shares. The
fourth series of Preferred Stock shall be designated “Series D Preferred Stock” and shall consist
of Thirteen Million Eight Hundred Eighty-Seven Thousand Seven Hundred Sixteen (13,887,716) shares.

ARTICLE IV

     The terms and provisions of the Common Stock and Preferred Stock are as follows:

     1. Definitions. For purposes of this Article IV, the following definitions shall
apply:

 

 

          (a) “Conversion Price” shall mean $1.10 per share for the Series A Preferred Stock,
$1.78 per share for the Series B Preferred Stock, $2.58 per share for the Series C Preferred Stock
and $2.80 per share for the Series D Preferred Stock (each subject to adjustment from time to time
as set forth elsewhere herein).

          (b) “Convertible Securities” shall mean any evidences of indebtedness, shares or other
securities (other than shares of Common Stock) convertible into or exchangeable for Common Stock.

          (c) “Corporation” shall mean Fluidigm Corporation.

          (d) “Dividend Rate” shall mean an annual rate of $0.11 per share for the Series A
Preferred Stock, an annual rate of $0.18 for the Series B Preferred Stock, an annual rate of $0.26
per share for the Series C Preferred Stock and an annual rate of $0.30 per share for the Series D
Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein).

          (e) “Liquidation Preference” shall mean $1.10 per share for the Series A Preferred
Stock, $1.78 per share for the Series B Preferred Stock, $2.58 per share for the Series C Preferred
Stock and $2.80 per share for the Series D Preferred Stock (each subject to adjustment from time to
time as set forth elsewhere herein).

          (f) “Options” shall mean rights, options or warrants to subscribe for, purchase or
otherwise acquire Common Stock or Convertible Securities.

          (g) “Original Issue Price” shall mean $1.10 per share for the Series A Preferred
Stock, $1.78 for the Series B Preferred Stock, $2.58 per share for the Series C Preferred Stock and
$2.80 per share for the Series D Preferred Stock (each subject to adjustment from time to time as
set forth elsewhere herein).

          (h) “Preferred Stock” shall mean the Series A Preferred Stock, Series B Preferred
Stock, the Series C Preferred Stock and the Series D Preferred Stock.

     2. Dividends.

          (a) Series D Preferred Stock. The holders of outstanding shares of Series D Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or
Common Stock (collectively, the “Junior Stock”) of the Corporation other than a dividend payable
solely in Common Stock. No distributions shall be made with respect to the Junior Stock during any
fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common
Stock, until all declared dividends on the Series D Preferred Stock have been paid or set apart for
payment to the holders of Series D Preferred Stock. The right to receive dividends on shares of
Series D Preferred Stock shall not be cumulative, and no right to such dividends shall accrue to
holders of Series D Preferred Stock by reason of the fact that dividends on said shares are not
declared or paid in any year.

-2-

 

          (b) Series C Preferred Stock. The holders of outstanding shares of Series C Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series A Preferred Stock, Series B Preferred Stock or Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
with respect to the Series A Preferred Stock, Series B Preferred Stock or Common Stock during any
fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common
Stock, until all declared dividends on the Series C Preferred Stock have been paid or set apart for
payment to the holders of Series C Preferred Stock. The right to receive dividends on shares of
Series C Preferred Stock shall not be cumulative, and no right to such dividends shall accrue to
holders of Series C Preferred Stock by reason of the fact that dividends on said shares are not
declared or paid in any year.

          (c) Series A Preferred Stock and Series B Preferred Stock. The holders of outstanding
shares of Series A Preferred Stock and Series B Preferred Stock shall be entitled to receive
dividends, when and as declared by the Board of Directors, out of any assets at the time legally
available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable in
preference and priority to any declaration or payment of any distribution on Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
with respect to the Common Stock, other than dividends payable solely in Common Stock, until all
declared dividends on the Preferred Stock have been paid or set apart for payment to the Preferred
Stock holders. Payment of any dividends to the holders of the Series A Preferred Stock and
Series B Preferred Stock shall be on a pro-rata, pari passu basis in proportion to the Dividend
Rates for the Series A Preferred Stock and Series B Preferred Stock, as applicable. The right to
receive dividends on shares of Series A Preferred Stock and Series B Preferred Stock shall not be
cumulative, and no right to such dividends shall accrue to holders of Series A Preferred Stock or
Series B Preferred Stock by reason of the fact that dividends on said shares are not declared or
paid in any year.

          (d) Distribution. For purposes of this Section 2, unless the context otherwise
requires, a “distribution” shall mean the transfer of cash or other property without consideration
whether by way of dividend or otherwise, payable other than in Common Stock, or the purchase or
redemption of shares of the Corporation other than (i) repurchase of shares of Common Stock issued
to or held by employees, consultants, officers and directors of the Corporation or its subsidiaries
upon termination of their employment or services pursuant to agreements providing for the right of
said repurchase and at the original purchase price paid by such employees, consultants, officers
and directors; and (ii) repurchase of Common Stock issued to or held by employees, officers,
directors or consultants of the Corporation or its subsidiaries pursuant to rights of first refusal
contained in agreements providing for such rights, provided that such repurchase is unanimously
approved by the Board of Directors; and (iii) any other repurchase or redemption of capital stock
of the corporation unanimously approved by the Board of Directors and approved by the holders of
the majority of the Common Stock and the holders of more than two-thirds (2/3) of the outstanding
shares of the Preferred Stock, voting as separate classes.

-3-

 

          (e) Common Stock. Dividends may be paid on the Common Stock as and when declared by
the Board of Directors, subject to the prior dividend rights of the Preferred Stock and Section 6
below.

          (f) Non-Cash Distributions. Whenever a distribution provided for in this Section 2
shall be payable in property other than cash, the value of such distribution shall be deemed to be
the fair market value of such property as determined in good faith by the Board of Directors.

          (g) Consent to Certain Repurchases. As authorized by Section 402.5(c) of the
California Corporations Code, Sections 502 and 503 of the California Corporations Code shall not
apply with respect to payments made by the Corporation in connection with (i) repurchase of shares
of Common Stock issued to or held by employees, consultants, officers and directors of the
Corporation or its subsidiaries upon termination of their employment or services pursuant to
agreements providing for the right of said repurchase and at the original purchase price paid by
such employees, consultants, officers and directors, and (ii) repurchase of Common Stock issued to
or held by employees, officers, directors or consultants of the Corporation or its subsidiaries
pursuant to rights of first refusal contained in agreements providing for such rights, provided
that such repurchase is unanimously approved by the Board of Directors, and (iii) any other
repurchase or redemption of capital stock of the Corporation unanimously approved by the Board of
Directors and approved by the holders of more than two-thirds (2/3) of the outstanding shares of
the Preferred Stock voting together as a single class.

     3. Liquidation Rights.

     In the event of any liquidation, dissolution or winding up of the Corporation, either
voluntary or involuntary, distribution of the assets of the Corporation legally available for
distribution to the Corporation’s shareholders shall be made in the following manner:

          (a) Series D Liquidation Preference. The holders of the Series D Preferred Stock
shall be entitled to receive, prior and in preference to any distribution of any of the assets of
the Corporation to the holders of the Common Stock, the Series A Preferred Stock, the Series B
Preferred Stock and the Series C Preferred Stock by reason of their ownership of such stock, an
amount per share for each share of Series D Preferred Stock held by them equal to the sum of
(i) the Liquidation Preference for such shares and (ii) all declared and unpaid dividends on such
share of Series D Preferred Stock. If the assets of the Corporation legally available for
distribution to the holders of the Series D Preferred Stock are insufficient to permit the payment
to such holders of the full amounts specified in this Section 3(a), then the entire assets of the
Corporation legally available for distribution shall be distributed with equal priority and
pro rata among the holders of the Series D Preferred Stock in proportion to the
full amounts they would otherwise be entitled to receive pursuant to this Section 3(a).

          (b) Series C Liquidation Preference. After payment to the holders of Series D
Preferred Stock of the full amounts specified in Section 3(a) above, the holders of the Series C
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the assets of the Corporation to the holders of the Common Stock, the Series A Preferred Stock and
the Series B Preferred Stock by reason of their ownership of such stock, an amount per share for
each

-4-

 

share of Series C Preferred Stock held by them equal to the sum of (i) the Liquidation
Preference for such shares and (ii) all declared and unpaid dividends on such share of Series C
Preferred Stock. If the remaining assets of the Corporation legally available for distribution to
the holders of the Series C Preferred Stock are insufficient to permit the payment to such holders
of the full amounts specified in this Section 3(b), then the entire remaining assets of the
Corporation legally available for distribution shall be distributed with equal priority and
pro rata among the holders of the Series C Preferred Stock in proportion to the
full amounts they would otherwise be entitled to receive pursuant to this Section 3(b).

          (c) Series B Liquidation Preference. After the payment to the holders of Series D
Preferred Stock and Series C Preferred Stock of the full amounts specified in Sections 3(a) and
3(b) above, the holders of the Series B Preferred Stock shall be entitled to receive, prior and in
preference to any distribution of any of the remaining assets of the Corporation to the holders of
the Common Stock and the Series A Preferred Stock by reason of their ownership of such stock, an
amount per share for each share of Series B Preferred Stock held by them equal to the sum of
(i) the Liquidation Preference for such shares and (ii) all declared and unpaid dividends on such
share of Series B Preferred Stock. If the remaining assets of the Corporation legally available
for distribution to the holders of the Series B Preferred Stock are insufficient to permit the
payment to such holders of the full amounts specified in this Section 3(c), then the entire
remaining assets of the Corporation legally available for distribution shall be distributed with
equal priority and pro rata among the holders of the Series B Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this
Section 3(c).

          (d) Series A Liquidation Preference. After the payment to the holders of Series D
Preferred Stock, the holders of Series C Preferred Stock and the holders of Series B Preferred
Stock of the full amounts specified in Sections 3(a), 3(b) and 3(c) above, the holders of the
Series A Preferred Stock shall be entitled to receive, prior and in preference to any distribution
of any of the remaining assets of the Corporation to the holders of the Common Stock by reason of
their ownership of such stock, an amount per share for each share of Series A Preferred Stock held
by them equal to the sum of (i) the Liquidation Preference for such shares and (ii) all declared
and unpaid dividends on such share of Series A Preferred Stock. If the remaining assets of the
Corporation legally available for distribution to the holders of the Series A Preferred Stock are
insufficient to permit the payment to such holders of the full amounts specified in this
Section 3(d), then the entire remaining assets of the Corporation legally available for
distribution shall be distributed with equal priority and pro rata among the
holders of the Series A Preferred Stock in proportion to the full amounts they would otherwise be
entitled to receive pursuant to this Section 3(d).

          (e) Remaining Assets. After the payment to the holders of Preferred Stock of the full
amounts specified in Sections 3(a), 3(b), 3(c) and 3(d) above, the entire remaining assets of the
Corporation legally available for distribution shall be distributed pro-rata to holders of
the Common Stock of the Corporation in proportion to the number of shares of Common Stock held by
them.

          (f) Shares Not Treated as Both Preferred Stock and Common Stock in Any Distribution.
Shares of Preferred Stock shall not be entitled to be converted into shares of Common Stock in
order to participate in any distribution, or series of distributions, as shares of Common

-5-

 

Stock, without first foregoing participation in the distribution, or series of distributions,
as shares of Preferred Stock.

          (g) Reorganization. For purposes of this Section 3, a liquidation, dissolution or
winding up of the Corporation shall be deemed to be occasioned by, or to include, (i) the
acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, any stock acquisition, reorganization, merger or
consolidation but excluding any merger effected exclusively for the purpose of changing the
domicile of the Corporation) other than a transaction or series of transactions in which the
holders of the voting securities of the Corporation outstanding immediately prior to such
transaction or series of transactions continue to retain (either by such voting securities
remaining outstanding or by such voting securities being converted into voting securities of the
surviving entity), as a result of shares in the Corporation held by such holders prior to such
transaction, at least fifty percent (50%) of the total voting power represented by the voting
securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (ii) a sale, transfer, lease or other conveyance of all
or substantially all of the assets of the Corporation.

          (h) Valuation of Non-Cash Consideration. If any assets of the Corporation distributed
to shareholders in connection with any liquidation, dissolution, or winding up of the Corporation
are other than cash, then the value of such assets shall be their fair market value as determined
in good faith by the Board of Directors, except that any securities to be distributed to
shareholders in a liquidation, dissolution, or winding up of the Corporation shall be valued as
follows:

               (i) If the securities are then traded on a national securities exchange or the Nasdaq Stock
Market System (or a similar national quotation system), then the value of the securities shall be
deemed to be to the average of the closing prices of the securities on such exchange or system over
the ten (10) trading day period ending five (5) trading days prior to the distribution;

               (ii) if the securities are actively traded over-the-counter, then the value of the securities
shall be deemed to be the average of the closing bid prices of the securities over the ten (10)
trading day period ending five (5) trading days prior to the distribution; or

               (iii) if there is no active public market for the securities, then the value of the securities
shall be deemed to be the fair market value thereof as determined in good faith by the Board of
Directors which determination shall include consideration of the illiquidity of the securities.

     In the event of a merger or other acquisition of the Corporation by another entity, the
distribution date shall be deemed to the date such transaction closes.

     For the purposes of this Section 3(h), “trading day” shall mean any day on which the exchange
or system on which the securities to be distributed are traded is open, and “closing prices” or
“closing bid prices” shall be deemed to be: (i) for securities traded primarily on the New York
Stock Exchange, the American Stock Exchange or Nasdaq, the last reported trade price or sale price,

-6-

 

as the case may be, at 4:00 p.m., New York time, on that day and (ii) for securities listed or
traded on other exchanges, markets and systems, the market price as of the end of the “regular
hours” trading period that is generally accepted as such for such exchange, market or system. If,
after the date hereof, the benchmark times generally accepted in the securities industry for
determining the market price of a stock as of a given trading day shall change from those set forth
above, the fair market value shall be determined as of such other generally accepted benchmark
times.

     4. Conversion. The holders of the Preferred Stock shall have conversion rights as
follows (the “Conversion Rights”):

          (a) Right to Convert. Subject to Section 4(c), each share of Preferred Stock shall be
convertible, at the option of the holder thereof, at any time after the date of issuance of such
share at the office of the Corporation or any transfer agent for the Preferred Stock, into that
number of fully-paid, nonassessable shares of Common Stock determined by dividing the Original
Issue Price for the relevant series by the Conversion Price for such series. (The number of shares
of Common Stock into which each share of Preferred Stock of a series may be converted is
hereinafter referred to as the “Conversion Rate” for each such series.) Upon any decrease or
increase in the Conversion Price for any series of Preferred Stock, as described in this Section 4,
the Conversion Rate for such series shall be appropriately increased or decreased.

          (b) Automatic Conversion. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then effective Conversion
Rate for such share (i) immediately prior to the closing of a firm commitment underwritten initial
public offering on Form S-1 (or successor form) filed under the Securities Act of 1933, as amended
(the “Securities Act”), covering the offer and sale of the Corporation’s Common Stock, provided
that the offering price per share is not less than $5.69 (as adjusted for stock splits or stock
dividends) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or
(ii) upon the receipt by the Corporation of a written consent or request for such conversion from
the holders of two-thirds of the shares of Preferred Stock then outstanding, or, if later, the
effective date for conversion specified in such requests (each of the events referred to in (i) and
(ii) being hereinafter referred to as an “Automatic Conversion Event”).

          (c) Mechanics of Conversion. No fractional shares of Common Stock shall be issued
upon conversion of Preferred Stock. In lieu of any fractional shares to which the holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then
fair market value of a share of Common Stock as determined by the Board of Directors. For such
purpose, all shares of Preferred Stock held by each holder of Preferred Stock shall be aggregated,
and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of
Preferred Stock shall be entitled to convert the same into full shares of Common Stock, and to
receive certificates therefor, he shall surrender the certificate or certificates therefor, duly
endorsed, at the office of the Corporation or of any transfer agent for the Preferred Stock, and
shall give written notice to the Corporation at such office that he elects to convert the same;
provided, however, that on the date of an Automatic Conversion Event, the
outstanding shares of Preferred Stock shall be converted automatically without any further action
by the holders of such shares and whether or not the certificates representing such shares are
surrendered to the Corporation or its transfer agent; provided further, however, that the
Corporation shall not be obligated to issue

-7-

 

certificates evidencing the shares of Common Stock issuable upon such Automatic Conversion
Event unless either the certificates evidencing such shares of Preferred Stock are delivered to the
Corporation or its transfer agent as provided above, or the holder notifies the Corporation or its
transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement
satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in
connection with such certificates. On the date of the occurrence of an Automatic Conversion Event,
each holder of record of shares of Preferred Stock shall be deemed to be the holder of record of
the Common Stock issuable upon such conversion, notwithstanding that the certificates representing
such shares of Preferred Stock shall not have been surrendered at the office of the Corporation,
that notice from the Corporation shall not have been received by any holder of record of shares of
Preferred Stock, or that the certificates evidencing such shares of Common Stock shall not then be
actually delivered to such holder.

     The Corporation shall, as soon as practicable after such delivery, or after such agreement and
indemnification, issue and deliver at such office to such holder of Preferred Stock, a certificate
or certificates for the number of shares of Common Stock to which he shall be entitled as aforesaid
and a check payable to the holder in the amount of any cash amounts payable as the result of a
conversion into fractional shares of Common Stock, plus any declared and unpaid dividends on the
converted Preferred Stock. Such conversion shall be deemed to have been made immediately prior to
the close of business on the date of such surrender of the shares of Preferred Stock to be
converted, and the person or persons entitled to receive the shares of Common Stock issuable upon
such conversion shall be treated for all purposes as the record holder or holders of such shares of
Common Stock on such date; provided, however, that if the conversion is in connection with
an underwritten offer of securities registered pursuant to the Securities Act the conversion may,
at the option of any holder tendering Preferred Stock for conversion, be conditioned upon the
closing of the sale of securities pursuant to such offering, in which event the person(s) entitled
to receive the Common Stock issuable upon such conversion of the Preferred Stock shall not be
deemed to have converted such Preferred Stock until immediately prior to the closing of the sale of
such securities.

          (d) Adjustments to Conversion Price for Diluting Issues.

               (i) Special Definition. For purposes of this Section 4(d), “Additional Shares of
Common” shall mean all shares of Common Stock issued (or, pursuant to Section 4(d)(iii), deemed to
be issued) by the Corporation after the filing of these Articles of Incorporation, other than:

                    (1) shares of Common Stock issued or issuable upon conversion of shares of Preferred Stock;

                    (2) shares of Common Stock issued or issuable to officers, directors and employees of, or
consultants and other service providers to, the Corporation pursuant to stock grants, option plans,
purchase plans or other employee stock incentive programs or arrangements approved by the Board of
Directors or upon exercise of options or warrants granted to such parties pursuant to any such
plan, program or arrangement;

-8-

 

                    (3) shares of Common Stock issued upon the exercise or conversion of Options or Convertible
Securities outstanding as of the date of the filing of these Articles of Incorporation;

                    (4) shares of Common Stock issued or issuable as a dividend or distribution on Preferred Stock
or pursuant to any event for which adjustment is made pursuant to Section 4(e), 4(f) or 4(g)
hereof;

                    (5) shares of Common Stock issued in a registered public offering under the Securities Act
pursuant to which all outstanding shares of Preferred Stock are automatically converted into Common
Stock pursuant to an Automatic Conversion Event;

                    (6) shares of Common Stock issued or issuable pursuant to the acquisition of another
corporation by the Corporation by merger, purchase of substantially all of the assets or other
reorganization or to a joint venture agreement, provided, that such issuances are unanimously
approved by the Board of Directors;

                    (7) shares of Common Stock issued or issuable to banks, equipment lessors or other financial
institutions pursuant to a commercial leasing or debt financing transaction approved by the Board
of Directors;

                    (8) shares of Common Stock issued or issuable in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements, or
strategic partnerships or relationships, if the issuance is approved by the Board of Directors; and

                    (9) shares of Common Stock issued or issuable upon conversion of up to $5 million in aggregate
principal amount (plus interest) of convertible promissory notes originally issued or issuable to
Biomedical Sciences Investment Fund Pte Ltd. or its affiliates and upon conversion of up to $3
million in aggregate principal amount (plus interest) of convertible promissory notes originally
issued or issuable to Invus, L.P. or its affiliates.

               (ii) No Adjustment of Conversion Price. No adjustment in the Conversion Price of a
particular series of Preferred Stock shall be made in respect of the issuance of Additional Shares
of Common unless the consideration per share (as determined pursuant to Section 4(d)(vi)) for an
Additional Share of Common issued or deemed to be issued by the Corporation is less than the
Conversion Price in effect on the date of, and immediately prior to such issue, for such series of
Preferred Stock.

               (iii) Deemed Issue of Additional Shares of Common. In the event the Corporation at
any time or from time to time after the date of the filing of these Articles of Incorporation shall
issue any Options or Convertible Securities or shall fix a record date for the determination of
holders of any class of securities entitled to receive any such Options or Convertible Securities,
then the maximum number of shares (as set forth in the instrument relating thereto without regard
to any provisions contained therein for a subsequent adjustment of such number) of Common Stock
issuable upon the exercise of such Options or, in the case of Convertible

 -9-

 

Securities, the conversion or exchange of such Convertible Securities or, in the case of
Options for Convertible Securities, the exercise of such Options and the conversion or exchange of
the underlying securities, shall be deemed to have been issued as of the time of such issue or, in
case such a record date shall have been fixed, as of the close of business on such record date,
provided that in any such case in which shares are deemed to be issued:

                    (1) no further adjustment in the Conversion Price of the Preferred Stock shall be made upon
the subsequent issue of Convertible Securities or shares of Common Stock in connection with the
exercise of such Options or conversion or exchange of such Convertible Securities;

                    (2) if such Options or Convertible Securities by their terms provide, with the passage of time
or otherwise, for any increase in the consideration payable to the Corporation, or decrease in the
number of shares of Common Stock issuable, upon the exercise, conversion or exchange thereof, the
Conversion Price of the Preferred Stock computed upon the original issue thereof (or upon the
occurrence of a record date with respect thereto), and any subsequent adjustments based thereon,
shall, upon any such increase or decrease becoming effective, be recomputed to reflect such
increase or decrease insofar as it affects such Options or the rights of conversion or exchange
under such Convertible Securities;

                    (3) no readjustment pursuant to clause (2) above shall have the effect of increasing the
Conversion Price of the Preferred Stock to an amount which exceeds the lower of (i) the Conversion
Price of the Preferred Stock on the original adjustment date, or (ii) the Conversion Price of the
Preferred Stock that would have resulted from any issuance of Additional Shares of Common between
the original adjustment date and such readjustment date;

                    (4) upon the expiration of any such Options or any rights of conversion or exchange under such
Convertible Securities which shall not have been exercised, the Conversion Price computed upon the
original issue thereof (or upon the occurrence of a record date with respect thereto) and any
subsequent adjustments based thereon shall, upon such expiration, be recomputed as if:

                         (A) in the case of Convertible Securities or Options for Common Stock, the only Additional
Shares of Common issued were the shares of Common Stock, if any, actually issued upon the exercise
of such Options or the conversion or exchange of such Convertible Securities and the consideration
received therefor was the consideration actually received by the Corporation for the issue of such
exercised Options plus the consideration actually received by the Corporation upon such exercise or
for the issue of all such Convertible Securities which were actually converted or exchanged, plus
the additional consideration, if any, actually received by the Corporation upon such conversion or
exchange, and

                         (B) in the case of Options for Convertible Securities, only the Convertible Securities, if
any, actually issued upon the exercise thereof were issued at the time of issue of such Options,
and the consideration received by the Corporation for the Additional Shares of Common deemed to
have been then issued was the consideration actually received by the Corporation for the issue of
such exercised Options, plus the consideration deemed to have been

-10-

 

received by the Corporation (determined pursuant to Section 4(d)(v)) upon the issue of the
Convertible Securities with respect to which such Options were actually exercised; and

                    (5) if such record date shall have been fixed and such Options or Convertible Securities are
not issued on the date fixed therefor, the adjustment previously made in the Conversion Price which
became effective on such record date shall be canceled as of the close of business on such record
date, and thereafter the Conversion Price shall be adjusted pursuant to this Section 4(d)(iii) as
of the actual date of their issuance.

               (iv) Adjustment of Conversion Price of Series D Preferred Stock Upon Issuance of
Additional Shares of Common.

                    (1) For so long as the Conversion Price of the Series D Preferred Stock is greater than $2.58
(as adjusted for subdivisions and combinations of the Common Stock and changes in the Common Stock
as set forth in Sections 4(e) and 4(g)) (the “Series D Ratchet Amount”), in the event this
Corporation shall issue Additional Shares of Common (including Additional Shares of Common deemed
to be issued pursuant to Section 4(d)(iii)) for a consideration per share less than the applicable
Conversion Price of the Series D Preferred Stock in effect on the date of and immediately prior to
such issue, but for a consideration per share equal to or greater than the Series D Ratchet Amount,
then, the Conversion Price of the Series D Preferred Stock shall be reduced concurrently with such
issue to a price (calculated to the nearest cent) equal to the per share price of the Additional
Shares of Common.

                    (2) In the event this Corporation shall issue Additional Shares of Common (including
Additional Shares of Common deemed to be issued pursuant to Section 4(d)(iii)) without
consideration or for a consideration per share less than the Series D Ratchet Amount, then, the
Conversion Price of the Series D Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series D Ratchet Amount (the “Adjusted Conversion Price”) and such Adjusted
Conversion Price shall be further reduced, concurrently with such issue, to a price (calculated to
the nearest cent) determined by multiplying such Adjusted Conversion Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately prior to
such issue plus the number of shares of Common Stock which the aggregate consideration received by
the Corporation for the total number of Additional Shares of Common so issued would purchase at
such Adjusted Conversion Price, and the denominator of which shall be the number of shares of
Common Stock outstanding immediately prior to such issue plus the number of such Additional Shares
of Common so issued. For the purposes of this Section 4(d)(iv)(2), all shares of Common Stock
issuable upon exercise of outstanding Options or the conversion of outstanding Convertible
Securities and shares of Preferred Stock, and all Additional Shares of Common deemed issued
pursuant to Section 4(d)(iii) hereof, shall be deemed to be outstanding. Section 4(d)(iv)(3) shall
govern adjustments to the Conversion Price of the Series D Preferred Stock after the first
adjustment to the Conversion Price of the Series D Preferred Stock pursuant to this Section
4(d)(iv)(2).

                    (3) After any adjustment to the Conversion Price of the Series D Preferred Stock pursuant to
Section 4(d)(iv)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to

-11-

 

Section 4(d)(iii)) without consideration or for a consideration per share less than Conversion
Price of the Series D Preferred Stock in effect on the date of and immediately prior to such issue,
then, the Conversion Price of the Series D Preferred Stock shall be reduced concurrently with such
issue, to a price (calculated to the nearest cent) determined by multiplying such Conversion Price
by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of shares of Common Stock which the aggregate
consideration received by the Corporation for the total number of Additional Shares of Common so
issued would purchase at such Conversion Price, and the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such
Additional Shares of Common so issued. For the purposes of this Section 4(d)(iv)(3), all shares of
Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding
Convertible Securities and shares of Preferred Stock, and all Additional Shares of Common deemed
issued pursuant to Section 4(d)(iii) hereof, shall be deemed to be outstanding.

               (v) Adjustment of Conversion Price of Series A, B and C Preferred Stock. In the event
this Corporation shall issue Additional Shares of Common (including Additional Shares of Common
deemed to be issued pursuant to Section 4(d)(iii)) without consideration or for a consideration per
share less than the applicable Conversion Price of the Series A Preferred Stock, Series B Preferred
Stock or Series C Preferred Stock in effect on the date of and immediately prior to such issue,
then, the Conversion Price of the Series A Preferred Stock, Series B Preferred Stock or Series C
Preferred Stock (if affected) shall be reduced, concurrently with such issue, to a price
(calculated to the nearest cent) determined by multiplying such Conversion Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately prior to
such issue plus the number of shares of Common Stock which the aggregate consideration received by
the Corporation for the total number of Additional Shares of Common so issued would purchase at
such Conversion Price, and the denominator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of such Additional Shares of Common so
issued. For the purposes of this Section 4(d)(v), all shares of Common Stock issuable upon
exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares
of Preferred Stock, and all Additional Shares of Common deemed issued pursuant to Section 4(d)(iii)
hereof, shall be deemed to be outstanding.

               (vi) Determination of Consideration. For purposes of this Section 4(d), the
consideration received by the Corporation for the issue (or deemed issue) of any Additional Shares
of Common shall be computed as follows:

                    (1) Cash and Property. Such consideration shall:

                         (A) insofar as it consists of cash, be computed at the aggregate amount of cash received by
the Corporation before deducting reasonable discounts, commissions or other expenses allowed, paid
or incurred by the Corporation for any underwriting or otherwise in connection with such issue (or
deemed issue);

                         (B) insofar as it consists of property other than cash, be computed at the fair market value
thereof at the time of such issue, as determined in good faith by the Board of Directors; and

 -12-

 

                         (C) in the event Additional Shares of Common are issued together with other shares or
securities or other assets of the Corporation for consideration which covers both, be the
proportion of such consideration so received, computed as provided in clauses (A) and (B) above, as
reasonably determined in good faith by the Board of Directors.

                    (2) Options and Convertible Securities. The consideration per share received by the
Corporation for Additional Shares of Common deemed to have been issued pursuant to
Section 4(d)(iii) shall be determined by dividing

                         (X) the total amount, if any, received or receivable by the Corporation as consideration for
the issue of such Options or Convertible Securities, plus the minimum aggregate amount of
additional consideration (as set forth in the instruments relating thereto, without regard to any
provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible
Securities, or in the case of Options for Convertible Securities, the exercise of such Options for
Convertible Securities and the conversion or exchange of such Convertible Securities by

                         (Y) the maximum number of shares of Common Stock (as set forth in the instruments relating
thereto, without regard to any provision contained therein for a subsequent adjustment of such
number) issuable upon the exercise of such Options or the conversion or exchange of such
Convertible Securities.

          (e) Adjustments for Subdivisions or Combinations of Common Stock. In the event the
outstanding shares of Common Stock shall be subdivided (by stock split, by payment of a stock
dividend or otherwise), into a greater number of shares of Common Stock, the Conversion Price of
each series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently
with the effectiveness of such subdivision, be proportionately decreased. In the event the
outstanding shares of Common Stock shall be combined (by reclassification or otherwise) into a
lesser number of shares of Common Stock, the Conversion Prices in effect immediately prior to such
combination shall, concurrently with the effectiveness of such combination, be proportionately
increased.

          (f) Adjustments for Subdivisions or Combinations of Preferred Stock. In the event the
outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock
split, by payment of a stock dividend or otherwise), into a greater number of shares of Preferred
Stock, the Dividend Rate, Original Issue Price and Liquidation Preference of the affected series of
Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the
effectiveness of such subdivision, be proportionately decreased. In the event the outstanding
shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or
otherwise) into a lesser number of shares of Preferred Stock, the Dividend Rate, Original Issue
Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately
prior to such combination shall, concurrently with the effectiveness of such combination, be
proportionately increased.

-13-

 

          (g) Adjustments for Reclassification, Exchange and Substitution. Subject to Section 3
above (“Liquidation Rights”), if the Common Stock issuable upon conversion of the Preferred Stock
shall be changed into the same or a different number of shares of any other class or classes of
stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision
or combination of shares provided for above), then, in any such event, in lieu of the number of
shares of Common Stock which the holders would otherwise have been entitled to receive, each holder
of such Preferred Stock shall have the right thereafter to convert such shares of Preferred Stock
into a number of shares of such other class or classes of stock which a holder of the number of
shares of Common Stock deliverable upon conversion of such series of Preferred Stock immediately
before that change would have been entitled to receive in such reorganization or reclassification,
all subject to further adjustment as provided herein with respect to such other shares.

          (h) No Impairment. The Corporation will not through any reorganization, transfer of
assets, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms to be observed or performed
hereunder by the Corporation but will at all times in good faith assist in the carrying out of all
the provisions of this Section 4 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of Preferred Stock against
impairment. Notwithstanding the foregoing, nothing in this Section 4(h) shall prohibit the
Corporation from amending its Articles of Incorporation with the requisite consent of its
shareholders and the board of directors.

          (i) Certificate as to Adjustments. Upon the occurrence of each adjustment or
readjustment of the Conversion Price pursuant to this Section 4, the Corporation at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based.
The Corporation shall, upon the written request at any time of any holder of Preferred Stock,
furnish or cause to be furnished to such holder a like certificate setting forth (i) such
adjustments and readjustments, (ii) the Conversion Price at the time in effect and (iii) the number
of shares of Common Stock and the amount, if any, of other property which at the time would be
received upon the conversion of Preferred Stock.

          (j) Notices of Record Date. In the event that this Corporation shall propose at any
time:

               (i) to declare any dividend or distribution upon its Common Stock, whether in cash, property,
stock or other securities, whether or not a regular cash dividend and whether or not out of
earnings or earned surplus;

               (ii) to effect any reclassification or recapitalization of its Common Stock outstanding
involving a change in the Common Stock; or

               (iii) to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a
liquidation, dissolution or winding up of the corporation pursuant to Section 3(f);

 -14-

 

then, in connection with each such event, this Corporation shall send to the holders of the
Preferred Stock at least 14 days’ prior written notice of the date on which a record shall be taken
for such dividend or distribution (and specifying the date on which the holders of Common Stock
shall be entitled thereto) or for determining rights to vote in respect of the matters referred to
in (ii) and (iii) above.

     Each such written notice shall be given by first class mail, postage prepaid, addressed to the
holders of Preferred Stock at the address for each such holder as shown on the books of this
Corporation.

     The right of the holders of the Preferred Stock to notice hereunder may be waived, either
prospectively or retroactively and either generally or in a particular instance, by the holders of
more than two-thirds (2/3) of the outstanding shares of the Preferred Stock voting together as a
single class.

          (k) Reservation of Stock Issuable Upon Conversion. The Corporation shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the
purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares
of Common Stock as shall from time to time be sufficient to effect the conversion of all then
outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued
shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding
shares of the Preferred Stock, the Corporation will take such corporate action as may, in the
opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purpose.

          (l) Waiver of Adjustment of Conversion Price. Notwithstanding anything herein to the
contrary, any downward adjustment of the Conversion Price of any series of Preferred Stock may be
waived, either prospectively or retroactively and either generally or in a particular instance, by
the consent or vote of the holders of more than two-thirds (2/3) of the outstanding shares of such
series. Any such waiver shall bind all future holders of shares of such series of Preferred Stock.

     5. Voting.

          (a) Restricted Class Voting. Except as otherwise expressly provided herein or as
required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together
and not as separate classes.

          (b) No Series Voting. Other than as provided herein or required by law, there shall
be no series voting.

          (c) Preferred Stock. Each holder of Preferred Stock shall be entitled to the number
of votes equal to the number of shares of Common Stock into which the shares of Preferred Stock
held by such holder could be converted as of the record date. The holders of shares of the
Preferred Stock shall be entitled to vote on all matters on which the Common Stock shall be
entitled to vote. Holders of Preferred Stock shall be entitled to notice of any shareholders’
meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be
permitted

-15-

 

and any fractional voting rights resulting from the above formula (after aggregating all
shares into which shares of Preferred Stock held by each holder could be converted), shall be
disregarded.

          (d) Common Stock. Each holder of shares of Common Stock shall be entitled to one vote
for each share thereof held.

          (e) Election of Directors. So long as at least 2,000,000 shares of Series D Preferred
Stock (as adjusted for stock splits, subdivisions, combinations or stock dividends with respect to
such shares) remain outstanding, the holders of the Series D Preferred Stock, voting as a separate
class, shall be entitled to elect one (1) member of the Corporation’s Board of Directors at each
meeting or pursuant to each consent of the Corporation’s shareholders for the election of
directors. So long as at least 2,000,000 shares of Series C Preferred Stock (as adjusted for stock
splits, subdivisions, combinations or stock dividends with respect to such shares) remain
outstanding, the holders of Series C Preferred Stock, voting as a separate class, shall be entitled
to elect three (3) members of the Corporation’s Board of Directors at each meeting or pursuant to
each consent of the Corporation’s shareholders for the election of directors. Any additional
members of the Corporation’s Board of Directors shall be elected by the holders of Common Stock,
Series A Preferred Stock and Series B Preferred Stock, voting together as a single class.

     6. Amendments and Changes Requiring Approval of Preferred Stock. As long as any of
the Preferred Stock shall be issued and outstanding, the Corporation shall not, without first
obtaining the approval (by vote or written consent as provided by law) of the holders of more than
two-thirds (2/3) of the outstanding shares of the Preferred Stock voting together as a single
class:

          (a) amend, alter or repeal any provision of the Articles of Incorporation or By-laws of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Preferred Stock or any series thereof;

          (b) enter into any transaction or series of related transactions deemed to be a liquidation,
dissolution or winding up of the Corporation pursuant to Section 3(f) above;

          (c) voluntarily liquidate or dissolve;

          (d) declare or pay any distribution (as defined in Section 2(d)) with respect to the Common
Stock of the Corporation;

          (e) permit any subsidiary of the Corporation to sell securities to a third party (other than
directors’ qualifying shares in the case of subsidiaries outside the United States);

          (f) increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Preferred Stock;

          (g) authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, liquidation, redemption,
conversion or other rights senior to or on a parity with any series of Preferred Stock or with
respect to voting senior to any series of Preferred Stock;

-16-

 

          (h) increase or decrease the authorized number of directors of the Corporation; or

          (i) amend this Section 6.

     7. Amendments and Changes Requiring the Approval of the Series D Preferred Stock.

          (a) As long as any of the Series D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of 60% of the outstanding shares of the Series D Preferred Stock:

               (i) amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
restrictions provided for the benefit of the Series D Preferred Stock in a manner different from
any other series of Preferred Stock; or

               (ii) amend this Section 7(a).

          (b) As long as any of the Series D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of a majority of the outstanding shares of the Series D Preferred Stock:

               (i) increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series D Preferred Stock;

               (ii) authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series D Preferred Stock or with respect to
voting senior to the Series D Preferred Stock;

               (iii) declare or pay any distribution (as defined in Section 2(d)) with respect to the Common
Stock or Preferred Stock of the Corporation;

               (iv) increase the authorized number of directors of the Corporation above eleven (11); or

               (v) amend this Section 7(b).

     8. Amendments and Changes Requiring the Approval of the Series C Preferred Stock. As
long as any of the Series C Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of two-thirds of the outstanding shares of the Series C Preferred Stock:

          (a) amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or

-17-

 

restrictions provided for the benefit of the Series C Preferred Stock in a manner different
from any other series of Preferred Stock;

          (b) increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series C Preferred Stock;

          (c) authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series C Preferred Stock or with respect to
voting senior to the Series C Preferred Stock;

          (d) declare or pay any distribution (as defined in Section 2(c)) with respect to the Common
Stock or Preferred Stock of the Corporation;

          (e) increase the authorized number of directors of the Corporation above eleven (11); or

          (f) amend this Section 8.

     9. Amendments and Changes Requiring the Approval of the Series B Preferred Stock. As
long as any of the Series B Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of two-thirds of the outstanding shares of the Series B Preferred Stock:

          (a) amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
restrictions provided for the benefit of the Series B Preferred Stock in a manner different from
any other series of Preferred Stock;

          (b) increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series B Preferred Stock; or

          (c) amend this Section 9.

     10. Status of Converted Stock. In the event any shares of Preferred Stock shall be
converted pursuant to Article 4 hereof, then the shares so converted shall be cancelled and shall
not be issuable by the Corporation. The Articles of Incorporation shall be appropriately amended
to effect the corresponding reduction in the Corporation’s authorized capital stock.

     11. Notices. Any notice required by the provisions of this Article IV to be given to
the holders of Preferred Stock shall be deemed given if deposited in the United States mail,
postage prepaid, and addressed to each holder of record at such holder’s address appearing on the
books of the Corporation.

-18-

 

ARTICLE V

     1. Limitation of Directors’ Liability. The liability of the directors of this
Corporation for monetary damages shall be eliminated to the fullest extent permissible under
California law.

     2. Indemnification of Corporate Agents. This Corporation is authorized to provide
indemnification of agents (as defined in Section 317 of the California Corporations Code) through
bylaw provisions, agreements with agents, votes of shareholders or disinterested directors or
otherwise, in excess of the indemnification otherwise permitted by Section 317 of the California
Corporations Code, subject only to the applicable limits set forth in Section 204 of the California
Corporations Code with respect to actions for breach of duty to this Corporation and its
shareholders.

     3. Repeal or Modification. Any repeal or modification of the foregoing provisions of
this Article V shall not adversely affect any right of indemnification or limitation of liability
permitted under California law relating to acts or omissions occurring prior to such repeal or
modification.

(THE GREAT SEAL OF THE STATE OF CALIFORNIA - OFFICE OF THE SECRETARY OF STATE)

-19-

 

EXHIBIT B

Form of New License Agreement

 

 

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

	 	 	 
	 
	 	8805. LICI.001
	 
	 	UAB Research Foundation

LICENSE AGREEMENT

     THIS LICENSE AGREEMENT (this “Agreement”) dated as of March 7, 2003 (the “Effective Date”), is
entered into between The UAB Research Foundation, an Alabama not for profit organization (“UABRF”),
having a place of business at 1120G Administration Building, 704 20th Street, Birmingham, Alabama
35294, and Fluidigm Corporation, a California corporation (“Fluidigm”), having a place of business
at 7100 Shoreline Court, South San Francisco, California 94080.

     WHEREAS, UABRF owns or has rights in certain technology regarding nanovolume crystallization
arrays.

     WHEREAS, UABRF and Oculus Pharmaceuticals, Inc. (“Oculus”) have entered into that certain
License Agreement dated as of September 21, 2001 (“Oculus Agreement”) pursuant to which UABRF has
granted to Oculus an exclusive license to the Oculus Agreement Technology (as defined below), on
the terms and conditions of the Oculus Agreement.

     WHEREAS,
UABRF and Oculus have terminated the Oculus Agreement effective as of January 30,
2003.

     WHEREAS, UABRF has licensed to Diversified Scientific, Inc. (“DSI”) rights in certain other
technology, which certain technology is identified in the attached Exhibit A (“UABRF/DSI
Technology”).

     WHEREAS, DSI is performing certain research pursuant to one or more grants, existing as of
December 19, 2002, between UAB (as defined below) and DSI under Defense Small Business Innovation
Research Program.

     WHEREAS, Fluidigm desires to obtain an exclusive worldwide license under the Licensed IP
Rights (as defined below), on the terms and conditions of this Agreement.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
herein contained, the parties agree as follows:

     1. DEFINITIONS

          1.1 “Affiliate” shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control with, such Person. A
Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, at least forty percent (40%) of the voting stock or other ownership interest of the other
Person, or if it directly or indirectly possesses the power to direct or cause the direction of the
management and policies of the other Person by any means whatsoever.

          1.2 “Confidential Information” shall mean, with respect to a party, all information of
any kind whatsoever, and all tangible and intangible embodiments thereof of any

 

 

kind whatsoever, which is disclosed by such party to the other party and is marked, identified as
or otherwise acknowledged to be confidential at the time of disclosure to the other party.
Notwithstanding the foregoing, Confidential Information of a party shall not include information
which the other party can establish by written documentation (a) to have been publicly known prior
to disclosure of such information by the disclosing party to the other party, (b) to have become
publicly known, without fault on the part of the other party, subsequent to disclosure of such
information by the disclosing party to the other party, (c) to have been received by the other
party at any time from a source, other than the disclosing party, rightfully having possession of
and the right to disclose such information, (d) to have been otherwise known by the other party
prior to disclosure of such information by the disclosing party to the other party, or (e) to have
been independently developed by employees or agents of the other party without access to or use of
such information disclosed by the disclosing party to the other party.

          1.3 “Fluidigm Series C Preferred Stock” shall have the meaning set forth in Section
1.9 of the Master Closing Agreement.

          1.4 “Licensed IP Rights” shall mean, collectively, the Licensed Patent Rights and the
Licensed Know-How Rights.

          1.5 “Licensed Know-How Rights” shall mean all trade secret and other know-how rights
in all information and data disclosed on or before the Effective Date that (i) is not generally
known (including, but not limited to, information and data regarding formulae, procedures,
protocols, techniques and results of experimentation and testing), (ii) is developed by Dr. Larry
DeLucas in his capacity as a UAB faculty member or by UAB personnel under the scientific direction
and scientific supervision of Dr. Larry DeLucas, and (iii) is necessary or useful for Fluidigm to
research, develop, make, use, sell or seek regulatory approval to market a composition, or to
practice any method or process, at any time (a) comprising the Oculus Agreement Technology or (b)
claimed or covered by in any issued patent or pending patent application within the Licensed Patent
Rights.

          1.6 “Licensed Patent Rights” shall mean (a) those certain patent applications and
patents listed on Exhibit B hereto; (b) all patent applications heretofore or hereafter
filed or having legal force in any country which claim any Oculus Agreement Technology; (c) all
patents that have issued or in the future issue from the patent applications described in clauses
(a) and (b) of this Section 1.6, including utility, model and design patents and certificates of
invention; and (d) all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patent applications and patents.

          1.7 “Master Closing Agreement” shall mean a Master Closing Agreement between
Fluidigm, UABRF and Oculus of even date hereof.

          1.8 “NanoScreen Patent Rights” shall mean (a) those certain patent applications and
patents listed on Exhibit B hereto; (b) all patents that have issued or in the future issue
from any such patent applications, including utility, model and design patents and certificates of
invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patent applications and patents.

 - 2 - 

 

          1.9 “Oculus Agreement Technology” shall mean collectively, the technology, processes,
inventions, trade secrets, know-how and other proprietary property described in Exhibit C
hereto.

          1.10 “Person” shall mean an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, pool, syndicate,
sole proprietorship, unincorporated organization, governmental authority or any other form of
entity not specifically listed herein.

          1.11 “Third Party” shall mean any Person other than UABRF, Fluidigm and their
respective Affiliates.

          1.12 “UAB” shall mean the University of Alabama at Birmingham.

          1.13 “UABRF/DSI
License Agreements” shall mean, collectively,
[***].

          1.14 “UAB Related Entities” shall mean and include UAB, UABRF, University Hospital,
The University of Alabama Health Services Foundation (“UAHSF”), Southern Research Institute and all
other entities within the UAB Medical Center, which are under the control of the Board of Trustees
of The University of Alabama or are associated with said Board of Trustees through an affiliation
agreement.

     2. REPRESENTATIONS AND WARRANTIES

          2.1 Mutual Representations and Warranties Each party hereby represents and warrants to
the other party as follows:

               2.1.1 Corporate Existence. Such party is a corporation duly organized, validly
existing and in good standing under the laws of the state in which it is incorporated.

               2.1.2 Authorization and Enforcement of Obligations. Such party (a) has the corporate
power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has
been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding
obligation, enforceable against such party in accordance with its terms.

               2.1.3 No Consents. All necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained by such party in connection with
this Agreement have been obtained.

               2.1.4 No Conflict. The execution and delivery of this Agreement and the performance of
such party’s obligations hereunder (a) do not conflict with or violate any

 - 3 - 

 

requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a
default under, any contractual obligation of it.

          2.2 UABRF Representations and Warranties. UABRF represents and warrants to
Fluidigm as follows:

               2.2.1
Ownership. UABRF is the sole owner of the Licensed IP Rights (other than those
listed under Item No. 3 of Exhibit B), and as of the Effective Date has no knowledge of any
Third Party having any license or other interest in such Licensed IP Rights. UABRF shall use its
commercially reasonable efforts to provide Fluidigm with (a) evidence of UABRF’s sole ownership of
those Licensed IP Rights listed under Item No. 3 of Exhibit B, and (b) a letter from DSI to
Fluidigm stating that DSI has no license or other interest in NanoScreen Patent Rights except to
the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants (as
defined below).

               2.2.2 No Injunction. No action, suit or proceeding before any court or government body
is instituted (or is pending) by any government authority or any other Person to restrain or
prohibit this Agreement or the consummation of the transactions contemplated hereby. No preliminary
or permanent injunction or other order issued by any federal or state court of competent
jurisdiction preventing this Agreement or the consummation of the transactions contemplated hereby
is in effect.

               2.2.3 No Infringement. As of the Effective Date, UABRF and Dr. Larry DeLucas (a) are
not aware of any Third Party patent, patent application or other intellectual property rights that
would be infringed by practicing any process or method or by making, using or selling any
composition which is claimed or disclosed in the Licensed Patent Rights or which constitutes
Licensed Know-How Rights; (b) are not aware of any infringement or misappropriation by a Third
Party of the Licensed IP Rights; and (c) are not aware of any license or other right granted to DSI
or any other Third Party under the NanoScreen Patent Rights. Provided however, UABRF has disclosed
to Fluidigm the potential infringement by DSI of the Licensed IP Rights to the extent necessary for
DSI to perform its research obligations pursuant to one or more grants (the “SBIR Grants”),
existing as of December 19, 2002, between UAB and DSI under the Defense Small Business Innovation
Research (SBIR) Program, with the understanding that neither DSI nor any other third party would
have the right to commercialize any results of such SBIR grants that would infringe the Licensed IP
Rights without first obtaining a license from Fluidigm under the Licensed IP Rights. Not later than
ten (10) days following the Effective Date, UABRF shall provide Fluidigm with copies of all
documents and instruments relating to such SBIR Grants.

     3. LICENSE GRANT

          3.1 Licensed IP Rights. UABRF hereby grants to Fluidigm an exclusive, perpetual,
irrevocable, royalty-free, worldwide license (including the right to grant sublicenses) under the
Licensed IP Rights. The license grant under the Licensed IP Rights (other than the NanoScreen
Patent Rights) is subject to the licenses previously and expressly granted by UABRF to DSI pursuant
to the UABRF/DSI License Agreements regarding the UABRF/DSI Technology only to the extent necessary
for DSI to exercise its license rights under the

 - 4 - 

 

UABRF/DSI Technology granted thereunder. The license grant under the NanoScreen Patent Rights is
not subject to any previously granted licenses other than those certain rights which may have been
granted to DSI to the extent necessary for DSI to perform its research obligations pursuant to the
SBIR Grants. To the extent any of the rights, title and interest in and to the Licensed IP Rights
can be neither assigned nor licensed by UABRF to Fluidigm without (a) the consent of, or (b)
breach by UABRF of any agreement with, any Third Party, UABRF hereby irrevocably waives and agrees
never to assert such non-assignable and non-licensable rights, title and interest against Fluidigm
or any of Fluidigm’s successors in interest to such non-assignable and non-licensable rights
during the term of this Agreement.

          3.2 Sublicenses. Fluidigm shall not sublicense the Licensed IP Rights prior to the
first (1st) anniversary of the Effective Date except in connection with settlement of any action or
claim relating to the technology that is the subject of the Licensed IP Rights. Fluidigm shall give
UABRF prompt written notice of each sublicense under this Agreement. Each sublicense shall be
subject to the terms and conditions of this Agreement.

          3.3 Availability of the Licensed IP Rights. UABRF shall provide Fluidigm with all
information available to UABRF regarding the Licensed IP Rights.

          3.4 Reservation of Rights.

               3.4.1 Research Use. UABRF hereby retains the right to, and this Agreement shall not
limit UABRF’s ability to, utilize the Licensed IP Rights for internal research, academic and
educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB,
for patient care at UAB and UAB Related Entities, and/or for the performance of services for
for-profit or not-for-profit institutions.

               3.4.2 Obligations to U.S. Government. UABRF agrees that during the term of this
Agreement UABRF shall not use the Licensed IP Rights in any manner except for internal research,
academic and educational purposes at UAB, UAB Related Entities and academic institution
collaborators of UAB, for patient care at UAB and UAB Related Entities, and/or for the performance
of services for for-profit or not-for-profit institutions as provided in Section 3.4.1 above and as
may be necessary or appropriate to fulfill the obligations of UABRF or UAB under the National
Institutes of Health (“NIH”) grant used to fund the research resulting in the development of
certain portion of the Licensed IP Rights. In determining the actions required under such grant,
UABRF shall consult with Fluidigm and keep Fluidigm informed, but UABRF shall have the ultimate
right to determine the necessary and appropriate actions relative thereto. UABRF’s rights to the
Licensed IP Rights for use in fulfilling UAB’s obligations under
the NIH grant shall only relate to
those portions of the Licensed IP Rights funded by such NIH grant.

          3.5 Non-Assertion Covenant. To the extent the research activities of DSI
conducted in accordance with the SBIR Grants infringe the rights granted to Fluidigm under this
Section 3, Fluidigm agrees not to assert such rights against DSI. Fluidigm agrees not to assert
against DSI such rights only to the extent expressly stated herein. No license or other right by
Fluidigm in favor of DSI shall be created hereunder by implication, estoppel or otherwise.

 - 5 - 

 

     4. LICENSE ISSUE FEE

     Within thirty (30) days after the Effective Date Fluidigm shall (a) pay UABRF the sum in cash
of [***] and (b) issue to UABRF such number of Fluidigm Series C
Preferred Stock as provided in Section 2.3 of the Master Closing Agreement.

     5. RESEARCH AND DEVELOPMENT OBLIGATIONS

          5.1 Research and Development Efforts. Fluidigm shall use commercially reasonable
efforts to research, develop and commercialize the Licensed IP Rights as Fluidigm determines
commercially feasible. Appendix 1 of the Sponsored Research Agreement sets forth the components of
Fluidigm’s Topaz System which Fluidigm plans to release commercially.

          5.2 Records. Fluidigm shall maintain records, in sufficient detail and in good
scientific manner, which shall reflect all work done and results achieved in the performance of its
research and development regarding the Licensed IP Rights (including all data in the form required
under all applicable laws and regulations).

          5.3 Reports. Within ninety (90) days following the end of each calendar year during
the term of this Agreement, Fluidigm shall prepare and deliver to UABRF a written summary report
which shall describe the research and development of the Licensed IP Rights during such year.

     6. CONFIDENTIALITY

          6.1 Confidential Information. During the term of this Agreement, and for a period of
five (5) years following the expiration or earlier termination hereof, each party shall maintain in
confidence all Confidential Information disclosed by the other party, and shall not use, disclose
or grant the use of the Confidential Information except on a need-to-know basis to those directors,
officers, employees, consultants, clinical investigators, contractors, (sub)licensees, distributors
or permitted assignees, to the extent such disclosure is reasonably necessary in connection with
such party’s activities as expressly authorized by this Agreement. To the extent that disclosure is
authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any
such person or entity to hold in confidence and not make use of the Confidential Information for
any purpose other than those permitted by this Agreement. Each party shall notify the other
promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential
Information.

          6.2 Terms of this Agreement. Except as otherwise provided in Section 6.1 or 6.3,
neither party shall disclose any terms or conditions of this Agreement to any third party without
the prior consent of the other party. Notwithstanding the foregoing, prior to execution of this
Agreement, the parties have agreed upon the substance of information that can be used to describe
the terms of this transaction, and each party may disclose such information, as modified by mutual
agreement from time to time, without the other party’s consent.

          6.3 Permitted Disclosures. The confidentiality obligations contained in this Section 6
shall not apply to the extent that the receiving party (the “Recipient”) is required (a) to
disclose information by law, order or regulation of a governmental agency or a court of

 - 6 - 

 

competent jurisdiction, or (b) to disclose information to any governmental agency for purposes of
obtaining approval to test or market a product, provided in either case that the Recipient shall
provide written notice thereof to the other party and sufficient opportunity to object to any such
disclosure or to request confidential treatment thereof.

     7. PATENTS

          7.1 Prosecution and Maintenance. Fluidigm shall be responsible for and shall
control, at its sole cost, the preparation, filing, prosecution, defense (including without
limitation prosecution, defense and settlement of any interference or opposition) and maintenance
of the Licensed Patent Rights. Fluidigm shall give UABRF an opportunity to review and comment on
the text of each patent application within the Licensed Patent Rights before filing, and shall
provide UABRF with a copy of such patent application as filed, together with notice of its filing
date and serial number. UABRF shall cooperate with Fluidigm, execute all lawful papers and
instruments and make all rightful oaths and declarations as may be necessary in the preparation,
prosecution and maintenance of the Licensed Patent Rights.

               Enforcement.

               7.2.1 Each party shall notify the other party of any infringement known to such party of any
Licensed Patent Rights and shall provide the other party with the available evidence, if any, of
such infringement.

               7.2.2 Fluidigm, at its sole expense, shall have the right to determine the appropriate course
of action to enforce the Licensed Patent Rights or otherwise abate the infringement thereof, to
take (or refrain from taking) appropriate action to enforce the Licensed Patent Rights, to control
any litigation or other enforcement action and to enter into, or permit, the settlement of any such
litigation or other enforcement action with respect to the Licensed Patent Rights, and shall
consider, in good faith, the interests of UABRF in so doing. UABRF shall cooperate with Fluidigm in
the execution of any action to enforce the Licensed Patent Rights. Fluidigm shall retain all monies
recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent
Rights.

     8. TERMINATION

          8.1 Expiration. Subject to the provisions of Section 8.2 below, this Agreement
shall expire on the expiration of the last to expire of the Licensed Patent Rights. Upon
expiration of this Agreement under this Section 8.1, Fluidigm shall have a paid-up,
exclusive, worldwide license under the Licensed Know-How Rights.

          8.2 Termination by Fluidigm. Fluidigm may terminate this Agreement, in its sole
discretion, upon thirty (30) days prior written notice to UABRF. Upon termination of this Agreement
by Fluidigm under this Section 8.2, Fluidigm shall have a paid-up, non-exclusive, worldwide license
under the Licensed Know-How Rights.

               Effect of Expiration or Termination. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or termination,
and the provisions of Sections 6, 7 and 9 shall survive the expiration or termination

 - 7 - 

 

of this Agreement. Except as the parties otherwise agree in writing, termination of this
Agreement shall not affect the Master Closing Agreement.

     9. INDEMNIFICATION

          9.1 Indemnification. Fluidigm shall defend, indemnify and hold the UABRF harmless from
all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs)
resulting from any claims, demands, actions and other proceedings by any Third Party to the extent
resulting from Fluidigm’s use of the Licensed IP Rights under this Agreement.

          9.2 Procedure. UABRF promptly shall notify Fluidigm of any claim, demand, action or
other proceeding for which UABRF intends to claim indemnification. Fluidigm shall have the right to
participate in, and to the extent Fluidigm so desires jointly with any other indemnitor similarly
noticed, to assume the defense thereof with counsel selected by Fluidigm; provided, however, that
UABRF shall have the right to retain its own counsel, with the fees and expenses to be paid by
UABRF, if representation of UABRF by the counsel retained by Fluidigm would be inappropriate due to
actual or potential differing interests between UABRF and any other party represented by such
counsel in such proceedings. The indemnity obligations under this Section 9 shall not apply to
amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is
effected without the prior express written consent of Fluidigm, which consent shall not be
unreasonably withheld or delayed. The failure to deliver notice to Fluidigm within a reasonable
time after notice of any such claim or demand, or the commencement of any such action or other
proceeding, if prejudicial to its ability to defend such claim, demand, action or other proceeding,
shall relieve such Indemnitor of any liability to UABRF under this Section 9 with respect thereto,
but the omission so to deliver notice to Fluidigm shall not relieve it of any liability that it may
have to UABRF other than under this Section 9. Fluidigm may not settle or otherwise consent to an
adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights
or interests of UABRF without the prior express written consent of UABRF, which consent shall not
be unreasonably withheld or delayed. UABRF, its employees and agents, shall reasonably cooperate
with Fluidigm and its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by this Section 9.

          9.3 Insurance. Fluidigm shall maintain insurance with respect to the research,
development and commercialization of products by Fluidigm pursuant to this Agreement in such
amount as Fluidigm customarily maintains with respect to the research, development and
commercialization of its similar products. Fluidigm shall maintain such insurance for so long as
it continues to research, develop or commercialize any products pursuant to this Agreement, and
thereafter for so long as Fluidigm customarily maintains insurance covering the research,
development or commercialization of its similar products.

     10. MISCELLANEOUS

          10.1 Notices. Any consent, notice or report required or permitted to be given or
made under this Agreement by one of the parties to the other shall be in writing and addressed to
such other party at its address indicated below, or to such other address as the addressee shall

 - 8 - 

 

have last furnished in writing to the addressor, and shall be effective upon receipt by the
addressee.

	 	 	 	 	 
	 

	 	If to UABRF:
	 	UAB Research Foundation
	 

	 	 	 	1120G Administration Building
	 

	 	 	 	704 20th Street
	 

	 	 	 	Birmingham, Alabama 35294
	 

	 	 	 	Attention: Director
	 
	 	 	 	 
	 

	 	If to Fluidigm:
	 	Fluidigm Corporation
	 

	 	 	 	7100 Shoreline Court
	 

	 	 	 	South San Francisco, California 94080
	 

	 	 	 	Attention: President
	 
	 	 	 	 
	 

	 	with a copy to:
	 	Fluidigm Corporation
	 

	 	 	 	7100 Shoreline Court
	 

	 	 	 	South San Francisco, California 94080
	 

	 	 	 	Attention: General Counsel

          10.2 Assignment. Except as otherwise expressly provided under this Agreement neither
this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred
(whether voluntarily, by operation of law or otherwise), without the prior express written consent
of the other party; provided, however, that either party may, without such consent, assign this
Agreement and its rights and obligations hereunder in connection with the transfer or sale of all
or substantially all of its business, or in the event of its merger, consolidation, change in
control or similar transaction. Any permitted assignee shall assume all obligations of its assignor
under this Agreement. Any purported assignment or transfer in violation of this Section 10.2 shall
be void.

          10.3 Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Alabama, without regard to the conflicts of law principles thereof.

          10.4 Entire Agreement. This Agreement and the Master Closing Agreement (together with
the Ancillary Agreements, as defined in the Master Closing Agreement) contain the entire
understanding of the parties with respect to the subject matter hereof. All express or implied
representations, agreements and understandings, either oral or written, heretofore made are
expressly superseded by this Agreement and the Master Closing Agreement. To the extent that any
provision of this Agreement conflicts with any provision of the Sponsored Research Agreement
between the parties of even date hereof (“Sponsored Research Agreement”), the applicable provision
of this Agreement shall control and supersede the applicable provision of the Sponsored Research
Agreement.

          10.5 Independent Contractors. Each party hereby acknowledges that the parties shall be
independent contractors and that the relationship between the parties shall not constitute a
partnership, joint venture or agency. Neither party shall have the authority to make any

 - 9 - 

 

statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other party, without the prior consent of the other party to do so.

          10.6 Waiver. The waiver by a party of any right hereunder, or of any failure to
perform or breach by the other party hereunder, shall not be deemed a waiver of any other right
hereunder or of any other breach or failure by the other party hereunder whether of a similar
nature or otherwise.

          10.7 Force Majeure. Neither party shall be held liable or responsible to the other
party nor be deemed to have defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure
or delay is caused by or results from causes beyond the reasonable control of the affected party
including but not limited to fire, floods, embargoes, war, acts of war (whether war be declared or
not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts
of God or acts, omissions or delays in acting by any governmental authority or the other party.

          10.8 Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	 	 	UAB RESEARCH FOUNDATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By
	 	/s/ (ILLEGIBLE)
 

	 	 
	 
	 

	 	Title
	 	Director	 	 
	 
	 	 	 	 	 	 
	 	 	FLUIDIGM CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By
	 	/s/ Gajus Worthington
 

	 	 
	 
	 

	 	Title
	 	President & CEO	 	 

	 	 	 
	Acknowledged and agreed to
	 	 
	this March 7, 2003.
	 	 
	 
	/s/ Dr. Larry DeLucas
 

Dr. Larry DeLucas

	 	 

 - 10 - 

 

EXHIBIT A

UABRF/DSI TECHNOLOGY

[***]

 - 11 - 

 

EXHIBIT B

PATENT RIGHTS

	1.	 	[***]

	2.	 	[***]

	3.	 	[***]

 - 12 - 

 

	4.	 	[***]

	5.	 	[***]

 - 13 - 

 

EXHIBIT C

OCULUS AGREEMENT TECHNOLOGY

	1.	 	[***]

	2.	 	[***]

	3.	 	Copies of all documentation describing the foregoing, in particular, drawings, operations
manuals.

 - 14 - 

 

EXHIBIT C

Form of Sponsored Research Agreement

 

 

8805.SRA.001         

UAB Research Foundation

FORM OF 

SPONSORED RESEARCH AGREEMENT

     THIS SPONSORED RESEARCH AGREEMENT (this “Agreement”) dated as of March       , 2003 (the “Effective
Date”), is entered into between The UAB Research Foundation, an Alabama not for profit organization
(the “UABRF”), having a place of business at 1120G Administration Building, 704 20th Street,
Birmingham, Alabama 35294, and Fluidigm Corporation, a California corporation (“Fluidigm”), having
a place of business at 7100 Shoreline Court, South San Francisco, California 94080. The parties
agree as follows:

     1. DEFINITIONS

          1.1 “Confidential Information” shall mean, with respect to a party, all information of
any kind whatsoever, and all tangible and intangible embodiments thereof of any kind whatsoever,
which is disclosed by such party to the other party and is marked, identified as or otherwise
acknowledged to be confidential at the time of disclosure to the other party. Notwithstanding the
foregoing, Confidential Information of a party shall not include information which the other party
can establish by written documentation (a) to have been publicly known prior to disclosure of such
information by the disclosing party to the other party, (b) to have become publicly known, without
fault on the part of the other party, subsequent to disclosure of such information by the
disclosing party to the other party, (c) to have been received by the other party at any time from
a source, other than the disclosing party, rightfully having possession of and the right to
disclose such information, (d) to have been otherwise known by the other party prior to disclosure
of such information by the disclosing party to the other party, or (e) to have been independently
developed by employees or agents of the other party without access to or use of such information
disclosed by the disclosing party to the other party (each, a “Confidentiality Exception”).

          1.2 “Derived” or “derived” shall mean obtained, developed, created, designed,
derived or resulting from, based upon or otherwise generated (whether directly or indirectly, or in
whole or in part).

          1.3 “Master Closing Agreement” shall mean a Master Closing Agreement between Fluidigm,
UABRF and Oculus Pharmaceuticals, Inc. of even date hereof.

          1.4 “Materials” shall mean the proprietary materials provided by one party to the
other under this Agreement, together with all derivatives and parts thereof.

          1.5
“Principal Investigator” shall mean [***].

          1.6 “Program” shall mean the research program described in Section
2.1.

          1.7 “Program Period” shall mean the period commencing on the Effective Date, and
continuing through the fifth (5th) anniversary of the Effective Date, unless terminated earlier as
provided below.

 1

 

          1.8 “Program Technology” shall mean, collectively, all inventions,
discoveries, data and information (whether patentable or not patentable) generated in connection
with the Program, excluding the Materials. Unless subject to a Confidentiality Exception, all
Program Technology shall be Confidential Information of UABRF.

          1.9 “Research Plan” shall mean the annual written research workplan for the Program.

     2. SPONSORED RESEARCH

          2.1 Statement of Work. During the Program Period, UABRF shall conduct the Program in
accordance with the Research Plan. The Research Plan for the first (1st) year of the Program is
attached hereto as Exhibit A. No later than ninety (90) days prior to each anniversary of
the Effective Date (other than the fifth (5th) anniversary thereof) during the term
of this Agreement the parties shall mutually agree upon the Research Plan for the upcoming year of
the Program and shall amend Exhibit A by attaching such mutually agreed upon Research Plan
thereto. Except as provided in this Section 2.1 or except by the mutual written agreement of the
parties, the Research Plan shall not be altered.

          2.2 Principal Investigator. UABRF shall conduct the Program under the
direction of the Principal Investigator. The Principal Investigator shall be responsible for the
supervision and administration of the Program, including all budgeting and revisions to the budget
in accordance with all applicable policies of UABRF. Fluidigm shall consider in good faith
utilizing on mutually acceptable terms and conditions the engineering capability available at the
Principal Investigator’s laboratory for the continuing development of Fluidigm’s Topaz
microprocessor product line as reasonably required by, but at the sole discretion of, Fluidigm at
additional compensation over and above the amounts set forth in Section 4.1 of this Agreement.

          2.3 Records and Reports.

               2.3.1 UABRF shall keep complete and accurate records of the work performed under this
Agreement in accordance with established good laboratory practices and appropriate for patent
purposes. Fluidigm shall have the right, upon reasonable notice and during reasonable business
hours, to inspect and make copies of such accounts, notes, data and records.

               2.3.2
Within [***] after the end of each calendar quarter
during the Program Period, UABRF shall prepare and provide Fluidigm with quarterly written reports
describing the work performed during such calendar quarter under this Agreement and all resulting
Program Technology. Within [***] after the expiration or earlier termination of the
Program Period, UABRF shall prepare and provide Fluidigm with a comprehensive written report
describing all work performed under this Agreement and all resulting Program Technology. At
Fluidigm’s request, upon reasonable notice, UABRF also shall provide interim summary reports and
copies of all data generated under this Agreement.

          2.4 Informal Consultations. At reasonable times during the Program Period, Fluidigm’s
representatives may consult informally with the Principal Investigator regarding the Program
personally, by telephone, email or other means of communication.

2

 

     3. MATERIAL TRANSFER

          3.1 Materials. Each party shall provide to the other party (the “Recipient”) those
Materials required to be provided under the Research Plan. The Recipient of any Materials hereby
acknowledges that, as between the parties, the other party is the sole owner or licensee of such
Materials.

          3.2 Permitted Use. The Recipient shall use the Materials solely as permitted under
the Research Plan and not for any other purpose. THE RECIPIENT UNDERSTANDS THAT THE MATERIALS ARE
PROVIDED SOLELY FOR CERTAIN RESEARCH USE ONLY AND HAVE NOT BEEN APPROVED FOR HUMAN USE. THE
RECIPIENT SHALL NOT ADMINISTER THE MATERIALS TO HUMANS IN ANY MANNER OR FORM. Provided however,
upon the Fluidigm Materials becoming commercially available (“Commercial Fluidigm Materials”), the
restrictions of this Section 3.2 shall terminate as to the Commercial Fluidigm
Materials, and the UABRF /UAB shall have the right to use the Commercial Fluidigm
Materials on the same terms and conditions as Fluidigm generally makes the Commercial Fluidigm
Materials commercially available to third parties.

          3.3 No Transfer. The Recipient shall not transfer the Materials to any third party
without the prior express written consent of the other party. The Recipient shall limit transfer
and disclosure of the Materials on a need to know basis, as reasonably necessary for the conduct
of the Program, to its directors, officers and employees who are bound by written agreements with
the Recipient to not use or transfer the Materials for any purpose other than those permitted by
this Agreement. The Recipient shall notify the other party promptly upon discovery of any
unauthorized use or transfer thereof.

          3.4 Return of Materials. Upon expiration or termination of the Program Period,
the Recipient shall promptly return or destroy (as requested by the other party) all
remaining Materials to the other party.

          3.5 No Warranty. THE RECIPIENT ACKNOWLEDGES THAT THE MATERIALS ARE EXPERIMENTAL IN
NATURE AND ARE PROVIDED “AS IS.” THE PARTY PROVIDING THE MATERIALS MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRES OR IMPLIED, WITH RESPECT TO THE MATERIALS OR THE USE THEREOF, AND DISCLAIMS ALL
IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE OR NONINFRINGEMENT.

     4. FUNDING

          4.1 Budget and Payment. Subject to the terms and conditions of this Agreement,
Fluidigm shall support the Program by an aggregate grant to UABRF of [***], payable in [***] equal quarterly installments of [***] on or before the thirtieth (30th) day of each calendar quarter after the Effective Date.
Fluidigm shall have no obligation to provide funds to UABRF in excess of such amount. All payments
by Fluidigm to UABRF under this Agreement shall be originated from a United States bank located in
the United States and made by bank wire transfer

3

 

to the following account: Account Name: UAB Research Foundation; Bank Name: First
Commercia1 Bank; ABA Number: [***], Account Number: [***].

          4.2 Accounting. Upon request by Fluidigm, UABRF shall provide to Fluidigm
a report of expenditures shown by major cost categories.

     5. PROGRAM TECHNOLOGY

          5.1 Ownership.

               5.1.1 All right, title and interest in all Program Technology (a) made or
conceived solely by employees or others acting on behalf of UABRF (the “UABRF Inventions”)
shall be owned solely by UABRF; (b) made or conceived solely by employees or others acting
on behalf of Fluidigm (the “Fluidigm Inventions”) shall be owned solely by Fluidigm; and
(c) made or conceived jointly by employees or others acting on behalf of Fluidigm and by
employees or others acting on behalf of UABRF (the “Joint Inventions”) shall be owned jointly
by Fluidigm and UABRF. Each party shall have the right, subject to the provisions of this
Agreement, to freely exploit, transfer, license or encumber its rights in any Joint
Inventions, and the patent rights and other intellectual property rights therein, without the
consent of, or payment or accounting to, the other party.

               5.1.2 The transfer of physical possession of any materials or technology
owned by, and the physical possession and use of any materials or technology by, Fluidigm or
UABRF, as the case may be, shall not be (nor construed as) a sale, lease, offer to sell or
lease, or
other transfer of title of such materials or technology to UABRF or Fluidigm, as the case
may be.

          5.2 Disclosure. UABRF promptly shall disclose to Fluidigm any Program
Technology made or conceived by or on behalf of UABRF, and provide Fluidigm with copies of
all information available to UABRF regarding such Program Technology.

          5.3 Options and Licenses.

               5.3.1 UABRF hereby grants to Fluidigm a nonexclusive, worldwide,
royalty-free license (together with the right to grant sublicenses), under UABRF’s rights in the
Program Technology, to use all unpatented Program Technology for all purposes.

               5.3.2 With respect to each discovery or invention comprising Program
Technology, UABRF hereby grants to Fluidigm an exclusive option to obtain an exclusive,
worldwide, royalty-bearing license (with the exclusive right to sublicense) under any issued
patents relating to such discovery or invention for all purposes. The option with respect to
each
such discovery or invention shall be exercisable for the [***] following disclosure
to
Fluidigm of all information available to UABRF regarding such discovery or invention. The
license shall be on mutually acceptable terms and conditions. Upon exercise by Fluidigm of
the
option with respect to each such discovery or invention, the parties shall negotiate in good
faith,
and shall use good faith efforts to execute a written agreement evidencing such license prior
to
the expiration of [***] days following the expiration of the one-year
option
term described above. The actual royalty rate shall be negotiated in good faith based on
reasonable factors including without limitation [***]

4

 

[***]. Fluidigm shall have the right to control the filing,
prosecution, maintenance and enforcement of all patent applications and patents that are so
licensed to Fluidigm.

               5.3.3 If Fluidigm fails to obtain a license under Section 5.3.2 with respect to any patent
rights, during the [***] day negotiation period under Section 5.3.2 (“Option
Negotiation Period”), UABRF for a [***] month period following the expiration of the Option
Negotiation Period shall [***].

          5.4 Patent Rights

               5.4.1 UABRF shall control the preparation, filing, prosecution and
maintenance of all patents and patent applications to the extent they claim UABRF Inventions or
Joint Inventions. Fluidigm shall advise UABRF no later than ninety (90) days after disclosure by
UABRF of a UABRF Invention or a Joint Invention whether it intends to reimburse UABRF for the
reasonable out of pocket costs of preparing, filing and prosecuting patent applications covering
such UABRF Invention or Joint Invention. If Fluidigm declines to reimburse UABRF for all reasonable
costs of preparing, filing and prosecuting a patent application for a patentable UABRF Invention or
Joint Invention in any jurisdiction, UABRF may do so at its sole cost, but such patent application
and patent shall be excluded from Fluidigm’s option to license under Section 5.3 above; provided,
however, UABRF shall not file or prosecute a patent application when Fluidigm has demonstrated to
UABRF that the filing or prosecution of such patent application would be prejudicial to the
optimization of such UABRF Invention or Joint Invention. UABRF shall give Fluidigm an opportunity
to review the text of, and shall reasonably consider Fluidigm’s comments with respect to, each
patent application for a UABRF Invention or a Joint Invention before filing, and shall supply
Fluidigm with a copy of such application as filed, together with notice of its filing date and
serial number. UABRF shall prepare, file and prosecute patent applications covering UABRF
Inventions or Joint Inventions in all jurisdictions requested by Fluidigm, provided that Fluidigm
has not declined to reimburse UABRF for all reasonable costs of preparing, filing and prosecuting
such patent applications.

               5.4.2 Fluidigm shall control, at its sole expense, the preparation, filing,
prosecution and maintenance of all patents and patent applications to the extent they claim
Fluidigm Inventions.

               5.4.3 Each party shall cooperate with the other party, execute all lawful
papers and instruments and make all rightful oaths and declarations as may be necessary in the
preparation, filing, prosecution maintenance and enforcement of all patents and patent
applications described in this Section 5.4.

 5

 

     6. CONFIDENTIALITY AND PUBLICATION

          6.1 Confidential Information. During the term of this Agreement, and for a
period of five (5) years following the expiration or earlier termination hereof, each party
shall
maintain in confidence all Confidential Information disclosed by the other party, and shall
not
use, disclose or grant the use of the Confidential Information except on a need-to-know
basis to
those directors, officers, employees, consultants, clinical investigators, contractors,
(sub)licensees, distributors or permitted assignees, to the extent such disclosure is
reasonably
necessary in connection with such party’s activities as expressly authorized by this
Agreement.
To the extent that disclosure is authorized by this Agreement, prior to disclosure, each
party
hereto shall obtain agreement of any such person or entity to hold in confidence and not
make
use of the Confidential Information for any purpose other than those permitted by this
Agreement. Each party shall notify the other promptly upon discovery of any unauthorized use
or disclosure of the other party’s Confidential Information.

          6.2 Terms of this Agreement. Except as otherwise provided in Section 6.1 or
6.3, neither party shall disclose any terms or conditions of this Agreement to any third
party
without the prior consent of the other party. Notwithstanding the foregoing, prior to
execution of
this Agreement, the parties shall agree upon the substance of information that can be used
to
describe the terms of this transaction, and each party may disclose such information, as
modified
by mutual agreement from time to time, without the other party’s consent.

          6.3 Permitted Disclosures. The confidentiality obligations contained in this
Section 6 shall not apply to the extent that the receiving party is required (a) to disclose
information by law, order or regulation of a governmental agency or a court of competent
jurisdiction, or (b) to disclose information to any governmental agency for purposes of
obtaining
approval to test or market a Product, provided in either case that the receiving party shall
provide
written notice thereof to the other party and sufficient opportunity to object to any such
disclosure or to request confidential treatment thereof.

          6.4 Publication. Fluidigm acknowledges UABRF’s interest in publishing
certain results of the Program to obtain recognition within the scientific community and to
advance the state of scientific knowledge. Each party also recognized their mutual interest
in
obtaining valid patent protection and protecting business interests. Consequently, if UABRF
desires to make a publication (including any oral disclosure made without obligation of
confidentiality) of any results of the Program, UABRF shall provide Fluidigm with a copy of
the
proposed written publication at least [***] days prior to submission for
publication, or
an outline of such oral disclosure at least [***] days prior to presentation.
Fluidigm shall
have the right (a) to propose modifications to the publication for patent reasons, and (b)
to
request a reasonable delay in publication in order to protect patentable information. If
Fluidigm
requests such a delay, UABRF shall delay submission or presentation of the publication for a
period of [***] days to enable patent applications to be prepared and filed. Upon the
expiration of such [***] day period (in the case of proposed written disclosures)
or
[***] day period (in the case of proposed oral disclosures) from receipt by Fluidigm,
UABRF shall be free to proceed with the written publication or the presentation,
respectively,
unless Fluidigm has requested the delay described above.

6

 

      7. TERM

          7.1 Expiration. Unless terminated earlier pursuant to Section 7.2, this
Agreement shall expire on the expiration of the Program Period.

          7.2 Termination for Cause. A party may terminate this Agreement upon or
after a material breach of this Agreement by the other party, if the breaching party has not
cured
such breach within thirty (30) days after notice thereof from the other party.

          7.3 Effect of Expiration and Termination. Expiration or termination of this
Agreement shall not relieve the parties of any obligation accruing prior to such expiration or
termination. The provisions of Sections 5, 6 and 8 shall survive the expiration or termination
of this Agreement. Except as the parties otherwise agree in writing, termination of this
Agreement shall not affect the Master Closing Agreement.

          7.4 Outstanding Commitments. Upon the giving of notice of termination by
either party, UABRF shall use best efforts to limit or terminate any outstanding
commitments in
connection with the Program. Fluidigm shall reimburse UABRF for all direct costs incurred by
it for all work performed through the effective termination date, and for all
outstanding
obligations which cannot be cancelled; provided, however, that Fluidigm’s aggregate
funding
obligation under this Agreement shall not exceed the amount set forth in Section 4.1 above.
Within thirty (30) days after the effective date of termination, UABRF shall furnish Fluidigm
with a final statement for settlement of all costs to be reimbursed. This statement may
include
costs incurred before the notice of termination was given but which were not yet billed. If
funds
received by UABRF exceed expenses incurred, UABRF shall reimburse Fluidigm for any such
excess funds at the time such final statement is furnished to Fluidigm.

     8. INDEMNIFICATION

          8.1 Indemnification.

               8.1.1 Fluidigm shall defend, indemnify and hold UABRF harmless from
all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs)
resulting from any claims, demands, actions and other proceedings by any unaffiliated third
party
to the extent resulting from Fluidigm’s gross negligence or willful misconduct under this
Agreement or use of the UABRF Materials or UABRF Confidential Information.

               8.1.2 UABRF shall (to the fullest extent to which University of Alabama
at Birmingham has the right under applicable law to do so) defend, indemnify and
hold Fluidigm
harmless from all losses, liabilities, damages and expenses (including reasonable
attorneys, fees
and costs) resulting from any claims, demands, actions and other proceedings by any
unaffiliated
third party to the extent resulting from UABRF’s gross negligence or willful misconduct under
the Agreement, or use of the Fluidigm Materials or Fluidigm Confidential
Information.

               8.1.3 A party (the “Indemnitee”) that intends to claim indemnification
under this Section 8.1 shall promptly notify the other party (the “Indemnitor”) of any
liability or
action in respect of which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so
desires,

 7

 

jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel
selected by the Indemnitor; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such
Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or
potential differing interests between such Indemnitee and any other party represented by such
counsel in such proceedings. The indemnity agreement in this Section 8.1 shall not apply to amounts
paid in settlement of any loss, claim, damage, liability or action if such settlement is effected
without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.
The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of
any such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor
of any liability to the Indemnitee under this Section 8.1, but the omission so to deliver notice to
the Indemnitor will not relieve it of any liability that it may have to the Indemnitee otherwise
than under this Section 8.1. The Indemnitor may not settle the action or
otherwise consent to an adverse judgment in such action that diminishes the rights or interests of
the Indemnitee without the express written consent of the Indemnitee. The Indemnitee, its employees
and agents, shall cooperate fully with the Indemnitor and its legal representatives in the
investigation and defense of any action, claim or liability covered by this indemnification.

          8.2 Representation. UABRF hereby represents that to the knowledge of UABRF and
the Principal Investigator the rights and obligations of UABRF under this Agreement do not conflict
with rights and obligations provided under other agreements which it has with third parties,
including the federal and local governments. During the Program Period (or while Fluidigm is
providing any subsequent funding), neither UABRF nor the Principal Investigator shall enter into
any other agreements which conflict with rights and obligations provided hereunder, including any
rights and obligations which survive termination hereto. UABRF shall enter into written agreements
with its employees. consultants and such others as is necessary to obtain ownership of inventions,
discoveries and other useful research results, products and processes made by them pursuant to
activity carried out in connection with the Program.

     9. MISCELLANEOUS

          9.1 Notices. Any consent, notice or report required or permitted to be given or
made under this Agreement by one of the parties to the other shall be in writing and addressed to
such other party at its address indicated below, or to such other address as the addressee shall
have last furnished in writing to the addressor, and shall be effective upon receipt by the
addressee.

	 	If to UABRF: 	 	UAB Research Foundation

1120G Administration Building

 704 20th Street
 Birmingham, Alabama 35294

Attention: Director

8

 

	 	If to Fluidigm: 	 	Fluidigm Corporation
 7100 Shoreline Court

South San Francisco, California 94080
 Attention: President
	 
	 	with a copy to: 	 	Fluidigm Corporation
 7100 Shoreline Court

South San Francisco, California 94080
 Attention: General Counsel

          9.2 Assignment. Except as otherwise expressly provided under this
Agreement neither this Agreement nor any right or obligation hereunder may be assigned or
otherwise transferred (whether voluntarily, by operation of law or otherwise), without the
prior
express written consent of the other party; provided, however, that either party may,
without such consent, assign this Agreement and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its business, or in the
event of its merger, consolidation, change in control or similar transaction. Any permitted
assignee shall assume all obligations of its assignor under this Agreement. Any purported
assignment or transfer in violation of this Section 9.2 shall be void.

          9.3 Applicable Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Alabama, without regard to the conflicts of law
principles thereof.

          9.4 Entire Agreement. This Agreement and the Master Closing Agreement
(together with the Ancillary Agreements, as defined in the Master Closing Agreement) contain
the entire understanding of the parties with respect to the subject matter hereof. All express
or
implied representations, agreements and understandings, either oral or written, heretofore
made
are expressly superseded by this Agreement and the Master Closing Agreement.

          9.5 Independent Contractors. Each party hereby acknowledges that the parties
shall be independent contractors and that the relationship between the parties shall not
constitute
a partnership, joint venture or agency. Neither party shall have the authority to make any
statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other party, without the prior consent of the other party to do so.

          9.6 Waiver. The waiver by a party of any right hereunder, or of any failure to
perform or breach by the other party hereunder, shall not be deemed a waiver of any other
right
hereunder or of any other breach or failure by the other party hereunder whether of a similar
nature or otherwise.

          9.7 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

9

 

     IN WITNESS WHEREOF, the parties have duly executed and delivered this Agreement as of the date
first written above.

	 	 	 	 	 
	 	UAB RESEARCH FOUNDATION

 	 
	 	By:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	FLUIDIGM CORPORATION

 	 
	 	By:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	Acknowledged and agreed to
 this
March    , 2003.

 	 	 
	
 	 	 
	Dr. [***], 	 	 
	Principal Investigator 	 	 

10

 

	 	 	 	 	 

EXHIBIT A

RESEARCH PLAN

[***]

11

 

APPENDIX 1 
(To Exhibit A
(“Research Plan”)

[***]

	 	 	 	 	 
	Part Number	 	Item	 	Quantity
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

Other Materials included: [***]

12

 

EXHIBIT D 

PATENTS AND PATENT APPLICATIONS

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]